[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 76 of about 76
1. Puppa G, Maisonneuve P, Sonzogni A, Masullo M, Chiappa A, Valerio M, Zampino MG, Franceschetti I, Capelli P, Chilosi M, Menestrina F, Viale G, Pelosi G: Independent prognostic value of fascin immunoreactivity in stage III-IV colonic adenocarcinoma. Br J Cancer; 2007 Apr 10;96(7):1118-26
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Independent prognostic value of fascin immunoreactivity in stage III-IV colonic adenocarcinoma.
  • In this study, we investigated the expression of fascin in 228 advanced colonic adenocarcinoma patients with a long follow-up.
  • Fascin correlated significantly with sex, tumour grade and stage, mucinous differentiation, number of metastatic lymph nodes, extranodal tumour extension, and the occurrence of distant metastases.
  • [MeSH-major] Adenocarcinoma / metabolism. Carrier Proteins / metabolism. Colonic Neoplasms / metabolism. Microfilament Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1993 Feb 15;71(4):1368-83 [8435813.001]
  • [Cites] J Cutan Pathol. 2002 Aug;29(7):430-8 [12139639.001]
  • [Cites] Am J Pathol. 1996 Feb;148(2):593-600 [8579121.001]
  • [Cites] In Vivo. 1996 Mar-Apr;10(2):153-60 [8744794.001]
  • [Cites] J Cell Biol. 1996 Sep;134(5):1271-81 [8794867.001]
  • [Cites] Hum Pathol. 1996 Nov;27(11):1124-34 [8912819.001]
  • [Cites] Dis Colon Rectum. 1997 Jan;40(1):15-24 [9102255.001]
  • [Cites] Mol Biol Cell. 1997 Nov;8(11):2345-63 [9362073.001]
  • [Cites] Mol Biol Cell. 1998 May;9(5):993-1006 [9571235.001]
  • [Cites] J Cell Biol. 1998 Oct 5;143(1):121-33 [9763425.001]
  • [Cites] J Biol Chem. 1999 Feb 26;274(9):5443-53 [10026156.001]
  • [Cites] CA Cancer J Clin. 2004 Nov-Dec;54(6):295-308 [15537574.001]
  • [Cites] Ann Surg. 2002 Oct;236(4):416-21; discussion 421 [12368669.001]
  • [Cites] Am J Pathol. 2003 Jan;162(1):69-80 [12507891.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):241-50 [12525515.001]
  • [Cites] Br J Cancer. 2003 Feb 24;88(4):537-47 [12592367.001]
  • [Cites] Eur J Cancer. 2003 Apr;39(6):718-27 [12651195.001]
  • [Cites] Lung Cancer. 2003 Nov;42(2):203-13 [14568688.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1572-82 [15117979.001]
  • [Cites] Histopathology. 1986 May;10(5):437-59 [3721406.001]
  • [Cites] J Cell Biol. 1986 Aug;103(2):631-40 [3525578.001]
  • [Cites] Cell Struct Funct. 1988 Oct;13(5):373-85 [3224379.001]
  • [Cites] Oncology. 2004;67(3-4):262-70 [15557788.001]
  • [Cites] Surg Oncol. 2004 Aug-Nov;13(2-3):93-101 [15572091.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):186-92 [15671545.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2597-605 [15814639.001]
  • [Cites] Int J Biochem Cell Biol. 2005 Sep;37(9):1787-804 [16002322.001]
  • [Cites] Hum Pathol. 2005 Jul;36(7):741-6 [16084942.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Nov 11;337(1):355-62 [16185662.001]
  • [Cites] Semin Oncol. 2005 Dec;32(6 Suppl 8):11-4 [16360006.001]
  • [Cites] Clin Colorectal Cancer. 2006 May;6(1):38-45 [16796790.001]
  • [Cites] Eur J Cardiothorac Surg. 2006 Sep;30(3):538-42 [16870459.001]
  • [Cites] J Clin Pathol. 2006 Sep;59(9):958-64 [16524962.001]
  • [Cites] BMC Cancer. 2006;6:241 [17029629.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1362-6 [14571738.001]
  • [Cites] J Histochem Cytochem. 2000 Feb;48(2):163-6 [10639482.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1739-57 [10738234.001]
  • [Cites] Br J Cancer. 2000 Oct;83(7):870-3 [10970687.001]
  • [Cites] Clin Exp Metastasis. 2000;18(1):83-8 [11206843.001]
  • [Cites] J Cell Biol. 2001 Mar 19;152(6):1169-82 [11257118.001]
  • [Cites] Nature. 2001 May 17;411(6835):375-9 [11357145.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2754-9 [11753948.001]
  • [Cites] Bioessays. 2002 Apr;24(4):350-61 [11948621.001]
  • [Cites] Am J Clin Pathol. 2002 Jul;118(1):52-9 [12109856.001]
  • [Cites] DNA Cell Biol. 1994 Aug;13(8):821-7 [8068206.001]
  • (PMID = 17375048.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Microfilament Proteins; 146808-54-0 / fascin
  • [Other-IDs] NLM/ PMC2360113
  •  go-up   go-down


2. Chen JS, Hsieh PS, Chiang JM, Yeh CY, Tsai WS, Tang R, Changchien CR, Wu RC: Clinical outcome of signet ring cell carcinoma and mucinous adenocarcinoma of the colon. Chang Gung Med J; 2010 Jan-Feb;33(1):51-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome of signet ring cell carcinoma and mucinous adenocarcinoma of the colon.
  • BACKGROUND: The purpose of this study was to evaluate the clinicopathologic features and prognosis of signet ring cell carcinoma (SCC) and non-SCC mucinous adenocarcinoma (MC) and to compare them with those of nonmucinous adenocarcinoma (NMC) of the colon.
  • The rate of spread of tumors in TNM stage IV via hematogenous routes (liver, lung, bone, and brain) was significantly lower in SCC patients (5/28, 17.9%) than in MC (40/104, 38.5%) and in NMC patients (417/694, 60.1%).
  • The role of resection for late stage SCC should be carefully evaluated.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Signet Ring Cell / pathology. Colonic Neoplasms / pathology

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20184795.001).
  • [ISSN] 2309-835X
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


3. dos Santos VM, de Carvalho EP, de Azevedo Cortes J, Osterne EM: Case report. Unsuspected and widespread colon cancer in a young woman. Rev Med Chil; 2008 Feb;136(2):221-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report. Unsuspected and widespread colon cancer in a young woman.
  • Liver and lung metastasis and local lymph node invasion are reported in a 26-year-old Brazilian woman with an asymptomatic colon cancer.
  • She was admitted complaining of right upper quadrant pain, and the diagnostic procedures revealed an unsuspected adenocarcinoma (stage IV) in the descending colon.
  • Late detection of colon cancer usually results in worst prognosis [corrected]
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Liver Neoplasms / secondary. Lung Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Rev Med Chil. 2008 Apr;136(4):544
  • (PMID = 18483677.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Chile
  •  go-up   go-down


Advertisement
4. Luo R, Giordano SH, Zhang DD, Freeman J, Goodwin JS: The role of the surgeon in whether patients with lymph node-positive colon cancer see a medical oncologist. Cancer; 2007 Mar 1;109(5):975-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of the surgeon in whether patients with lymph node-positive colon cancer see a medical oncologist.
  • BACKGROUND: Chemotherapy improves survival for patients with stage III colon cancer, but some older patients with lymph node-positive colon cancer do not see a medical oncologist and, thus, do not receive adjuvant chemotherapy.
  • METHODS: To evaluate the role of the surgeon in determining referrals to medical oncology among patients with stage III colon cancer, the authors conducted a retrospective cohort study of 6158 patients aged >or=66 years who were diagnosed with stage III colon cancer from 1992 through 1999 by using the Surveillance, Epidemiology, and End Results-Medicare linked database.
  • The individual surgeon characteristics that significantly predicted whether the patient saw a medical oncologist were year since graduation (<or=10 years vs >20 years; hazard ratio [HR], 1.60; 95% confidence interval [95% CI], 1.19-2.16), practicing in a teaching hospital (yes vs. no: HR; 1.30; 95% CI, 1.07-1.58), and volume of patients with colon cancer (<30 patients vs >or=121 patients; HR, 0.66; 95% CI, 0.46-0.94).
  • Interventions at the level of the surgeon may be appropriate to improve the care of patients with colon cancer.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Epidemiol. 2000 Dec;53(12):1258-67 [11146273.001]
  • [Cites] Oncologist. 2006 Oct;11(9):1025-33 [17030645.001]
  • [Cites] Cancer J. 2001 May-Jun;7(3):213-8 [11419029.001]
  • [Cites] N Engl J Med. 2001 Oct 11;345(15):1091-7 [11596588.001]
  • [Cites] Ann Intern Med. 2002 Mar 5;136(5):349-57 [11874307.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1716-8 [11919225.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1786-92 [11919235.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-3-18 [12187163.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-82-95 [12187173.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-96-103 [12187174.001]
  • [Cites] Ann Surg Oncol. 2003 Jul;10(6):606-15 [12839844.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4627-35 [14673052.001]
  • [Cites] Med Care. 2004 Sep;42(9):901-6 [15319616.001]
  • [Cites] Med Care. 1985 Aug;23(8):939-45 [4021579.001]
  • [Cites] Med Care. 1991 Jan;29(1):50-63 [1986177.001]
  • [Cites] BMJ. 1991 May 25;302(6787):1250-2 [2043851.001]
  • [Cites] Cancer. 1993 Jul 15;72(2):594-601 [8319193.001]
  • [Cites] Gastroenterology. 1994 Apr;106(4):899-906 [8143995.001]
  • [Cites] Br J Cancer. 1994 Aug;70(2):363-70 [8054286.001]
  • [Cites] N Engl J Med. 1994 Dec 15;331(24):1625-9 [7969344.001]
  • [Cites] Lancet. 1995 Apr 15;345(8955):939-44 [7715291.001]
  • [Cites] Med Care. 1996 May;34(5):479-89 [8614169.001]
  • [Cites] Health Serv Res. 1996 Apr;31(1):5-19 [8617610.001]
  • [Cites] Cancer. 1996 Aug 15;78(4):918-26 [8756390.001]
  • [Cites] J Fam Pract. 1997 Jul;45(1):47-53 [9228914.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):295-300 [9440756.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1349-55 [10334518.001]
  • [Cites] Lancet. 2005 Jan 8-14;365(9454):153-65 [15639298.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 17;97(16):1211-20 [16106026.001]
  • [Cites] JAMA. 2005 Dec 7;294(21):2703-11 [16333005.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):850-7 [11390534.001]
  • (PMID = 17265530.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA105631; United States / NCI NIH HHS / CA / R01 CA104949; United States / AHRQ HHS / HS / R24 HS011618
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS19823; NLM/ PMC1851914
  •  go-up   go-down


5. Oue N, Mitani Y, Aung PP, Sakakura C, Takeshima Y, Kaneko M, Noguchi T, Nakayama H, Yasui W: Expression and localization of Reg IV in human neoplastic and non-neoplastic tissues: Reg IV expression is associated with intestinal and neuroendocrine differentiation in gastric adenocarcinoma. J Pathol; 2005 Oct;207(2):185-98
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and localization of Reg IV in human neoplastic and non-neoplastic tissues: Reg IV expression is associated with intestinal and neuroendocrine differentiation in gastric adenocarcinoma.
  • Regenerating islet-derived family, member 4 (Reg IV) is a candidate marker for cancer and inflammatory bowel disease.
  • In the present study, immunohistochemical analysis of Reg IV was performed in various human neoplastic (n = 289) and non-neoplastic tissues.
  • In the stomach, foveolar epithelium was negative for Reg IV, whereas goblet cells of intestinal metaplasia and neuroendocrine cells at the base of intestinal metaplasia expressed Reg IV.
  • Neuroendocrine cells of the small intestine and colon showed strong expression of Reg IV, whereas goblet cells of the small intestine and colon showed weak or no expression of Reg IV.
  • Insulin-producing beta cells of the endocrine pancreas were positive for Reg IV.
  • Among 143 gastric adenocarcinomas, Reg IV expression was detected in 42 (29.4%) and was associated with both the intestinal mucin phenotype and neuroendocrine differentiation.
  • No association was found between Reg IV expression and clinical characteristics such as tumour stage and patient prognosis.
  • Of 36 colorectal adenocarcinomas, 13 (36.1%) were positive for Reg IV, which was associated with tumour stage (p = 0.0379, Fisher's exact test).
  • Expression of Reg IV was detected in 14 (93.3%) of 15 colorectal carcinoid tumours.
  • Reg IV expression was also detected in 5 (21.7%) of 23 ductal adenocarcinomas of the pancreas.
  • In contrast, lung cancers (n = 30) and breast cancers (n = 30) did not express Reg IV.
  • This is the first immunohistochemical analysis of the expression and distribution of Reg IV protein in human tumours.
  • These data suggest that Reg IV is expressed by gastrointestinal and pancreatic tumours, including adenocarcinomas and carcinoid tumours, and that Reg IV is associated with intestinal and neuroendocrine differentiation of the stomach and gastric carcinoma.
  • [MeSH-major] Adenocarcinoma / chemistry. Lectins, C-Type / analysis. Neoplasm Proteins / analysis. Stomach Neoplasms / chemistry
  • [MeSH-minor] Adenoma / chemistry. Biomarkers, Tumor / analysis. Blotting, Western / methods. Breast Neoplasms / chemistry. Carcinoid Tumor / chemistry. Cell Differentiation / physiology. Cell Line, Tumor. Colon / metabolism. Colorectal Neoplasms / chemistry. Female. Humans. Immunohistochemistry / methods. Intestine, Small / metabolism. Lung Neoplasms / chemistry. Pancreas / metabolism. Pancreatic Neoplasms / chemistry. Phenotype. RNA, Messenger / analysis. RNA, Neoplasm / analysis. Reverse Transcriptase Polymerase Chain Reaction / methods. Stomach / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • (PMID = 16086444.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Lectins, C-Type; 0 / Neoplasm Proteins; 0 / REG4 protein, human; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  •  go-up   go-down


6. Yamamoto T, Yoshioka N, Katoh Y, Iguchi M, Katoh M, Yamazaki M: [A case of sigmoid colon cancer that spread to the urinary bladder via the ureter]. Hinyokika Kiyo; 2005 Oct;51(10):673-5
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of sigmoid colon cancer that spread to the urinary bladder via the ureter].
  • A year ago, he underwent sidmoidectomy to cure sigmoid colon cancer diagnosed as stage IV.
  • Because the histopathological manifestation by transurethral resection of bladder tumor and that by the sidmoidectomy were consistent, it was considered that sigmoid colon cancer spread to the urinary bladder via the left ureter.
  • There have been only 4 reported cases of adenocarcinoma that multiplied in the ureter, and this is the fifth case report.
  • [MeSH-major] Adenocarcinoma / pathology. Lymph Nodes / pathology. Sigmoid Neoplasms / pathology. Ureteral Neoplasms / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Colon, Sigmoid / surgery. Diagnosis, Differential. Humans. Hydronephrosis / complications. Lymphatic Metastasis. Male. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16285621.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


7. Kabra N, Li Z, Chen L, Li B, Zhang X, Wang C, Yeatman T, Coppola D, Chen J: SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J Biol Chem; 2009 Jul 3;284(27):18210-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SirT1 is an inhibitor of proliferation and tumor formation in colon cancer.
  • Immunohistochemical staining revealed high level SirT1 in normal colon mucosa and benign adenomas.
  • SirT1 overexpression was observed in approximately 25% of stage I/II/III colorectal adenocarcinomas but rarely found in advanced stage IV tumors.
  • These results suggest a rationale for the use of SirT1 activators and inhibitors in the prevention and treatment of colon cancer.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Feb 17;403(6771):795-800 [10693811.001]
  • [Cites] Science. 2000 Sep 22;289(5487):2126-8 [11000115.001]
  • [Cites] Nature. 2001 Mar 8;410(6825):227-30 [11242085.001]
  • [Cites] Cell. 2001 Oct 19;107(2):137-48 [11672522.001]
  • [Cites] Cell. 2001 Oct 19;107(2):149-59 [11672523.001]
  • [Cites] Nature. 2003 Sep 11;425(6954):191-6 [12939617.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10794-9 [12960381.001]
  • [Cites] Cell. 2004 Feb 20;116(4):551-63 [14980222.001]
  • [Cites] EMBO J. 2004 Jun 16;23(12):2369-80 [15152190.001]
  • [Cites] Science. 2004 Jul 16;305(5682):390-2 [15205477.001]
  • [Cites] Science. 1990 Jan 19;247(4940):322-4 [2296722.001]
  • [Cites] Cancer Res. 1994 Nov 15;54(22):5947-52 [7954427.001]
  • [Cites] Nature. 2005 Mar 3;434(7029):113-8 [15744310.001]
  • [Cites] Cell Metab. 2005 Jul;2(1):67-76 [16054100.001]
  • [Cites] Cell Metab. 2005 Aug;2(2):105-17 [16098828.001]
  • [Cites] Cell. 2005 Nov 4;123(3):437-48 [16269335.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10457-63 [16288037.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(1):28-38 [16354677.001]
  • [Cites] Oncogene. 2006 Jan 12;25(2):176-85 [16170353.001]
  • [Cites] PLoS Biol. 2006 Feb;4(2):e31 [16366736.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4368-77 [16618762.001]
  • [Cites] Nat Cell Biol. 2006 Sep;8(9):1025-31 [16892051.001]
  • [Cites] Mol Cell Biol. 2006 Nov;26(21):8122-35 [16923962.001]
  • [Cites] Nature. 2006 Nov 16;444(7117):337-42 [17086191.001]
  • [Cites] Cell. 2006 Dec 15;127(6):1109-22 [17112576.001]
  • [Cites] Mol Cell. 2007 Feb 23;25(4):543-57 [17317627.001]
  • [Cites] Arch Dermatol Res. 2007 May;299(2):103-6 [17180656.001]
  • [Cites] Mol Cell. 2007 Jul 6;27(1):149-62 [17612497.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6612-8 [17638871.001]
  • [Cites] Oncogene. 2007 Aug 13;26(37):5489-504 [17694089.001]
  • [Cites] Biochem J. 2007 Nov 1;407(3):451-60 [17620057.001]
  • [Cites] Biotechnol J. 2007 Nov;2(11):1360-8 [17806102.001]
  • [Cites] Nature. 2007 Nov 29;450(7170):712-6 [18046409.001]
  • [Cites] Mol Biol Cell. 2008 Mar;19(3):1210-9 [18184747.001]
  • [Cites] PLoS One. 2008;3(4):e2020 [18414679.001]
  • [Cites] Cancer Cell. 2008 Oct 7;14(4):312-23 [18835033.001]
  • (PMID = 19433578.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA112215; United States / NCI NIH HHS / CA / R01 CA112215-03; United States / NCI NIH HHS / CA / CA121291; United States / NCI NIH HHS / CA / R01 CA121291; United States / NCI NIH HHS / CA / CA112215-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / RNA, Small Interfering; EC 3.5.1.- / SIRT1 protein, human; EC 3.5.1.- / Sirtuin 1; EC 3.5.1.- / Sirtuins; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2709385
  •  go-up   go-down


8. Scheiden R, Pescatore P, Wagener Y, Kieffer N, Capesius C: Colon cancer in Luxembourg: a national population-based data report, 1988-1998. BMC Cancer; 2005;5:52

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colon cancer in Luxembourg: a national population-based data report, 1988-1998.
  • BACKGROUND: Over the last two decades time trends in incidence rates of colorectal cancer, changes in the proportions of stage at diagnosis and changes in the anatomic sub-site distribution of colon cancers have been reported in some European countries.
  • In order to determine a strategy for early detection of colon cancer in the Grand-Duchy of Luxembourg, all consecutive colon adenocarcinomas diagnosed during the period 1988-1998 at a nation-wide level were reviewed.
  • METHODS: The population-based data of the national Morphologic Tumour Registry report all new high-grade adenomas (i.e. high-grade intraepithelial adenomatous neoplasias) and all consecutive new invasive adenocarcinomas of the colon diagnosed in the central department of pathology.
  • Attention has been focused on variations in incidence, stage, anatomical site distribution and survival rates.
  • RESULTS: Over the study period, 254 new colonic high-grade adenomas and 1379 new invasive adenocarcinomas were found; the crude incidence rates of colon adenocarcinomas grew steadily by 30%.
  • Comparing the two 5-year periods 1988-1992 and 1994-1998, the crude incidence rates of high-grade adenomas (stage 0) rose by 190%, that of stage I cases by 14.3%, stage II cases 12.9% and stage III cases 38.5%, whereas the crude incidence rates of stage IV cases decreased by 11.8%.
  • The high-grade adenoma/adenocarcinoma ratio increased.
  • The overall observed 5-year survival rate (stage I-IV) was 51 +/- 3% (95% confidence interval).
  • CONCLUSION: The increasing incidence rates of colon adenocarcinomas, the persistence of advanced tumour stages (stage III), the mortality rates which remain stable, and the changing trends in the age- and sub-site distribution underline the need for preventive measures at the age of 50 in asymptomatic patients to reduce mortality from colo(rectal) cancer.
  • [MeSH-major] Adenocarcinoma / epidemiology. Colonic Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Med. 2001 Dec 1;111(8):593-601 [11755501.001]
  • [Cites] Cancer. 2001 Nov 15;92(10):2547-54 [11745188.001]
  • [Cites] Oncologist. 2002;7(3):200-4 [12065791.001]
  • [Cites] Gut. 2002 Jul;51(1):60-4 [12077093.001]
  • [Cites] Int J Cancer. 2002 Oct 10;101(5):403-8 [12216066.001]
  • [Cites] Dis Colon Rectum. 2002 Sep;45(9):1249-54 [12352244.001]
  • [Cites] Am Surg. 2002 Oct;68(10):871-6 [12412713.001]
  • [Cites] Eur J Cancer Prev. 2002 Dec;11(6):529-34 [12457104.001]
  • [Cites] Gastroenterology. 2003 Feb;124(2):544-60 [12557158.001]
  • [Cites] Jpn J Clin Oncol. 2003 Jan;33(1):38-43 [12604723.001]
  • [Cites] Scand J Surg. 2003;92(1):5-9 [12705545.001]
  • [Cites] An Sist Sanit Navar. 2003 Jan-Apr;26(1):79-97 [12759713.001]
  • [Cites] N Z Med J. 2003 May 16;116(1174):U437 [12766783.001]
  • [Cites] Surg Endosc. 2003 Jun;17(6):886-90 [12658426.001]
  • [Cites] Dis Colon Rectum. 2003 Oct;46(10 Suppl):S32-43 [14530656.001]
  • [Cites] Am Surg. 2003 Oct;69(10):866-72 [14570365.001]
  • [Cites] Dig Dis. 2003;21(4):315-9 [14752221.001]
  • [Cites] W V Med J. 2003 Sep-Oct;99(5):182-6 [14959509.001]
  • [Cites] Int J Cancer. 2004 May 1;109(5):777-81 [14999789.001]
  • [Cites] Am Surg. 2004 Mar;70(3):259-64 [15055851.001]
  • [Cites] BMC Cancer. 2003 Oct 21;3:27 [14567762.001]
  • [Cites] IARC Sci Publ. 1992;(120):178-861 [1284601.001]
  • [Cites] Semin Surg Oncol. 1994 Jan-Feb;10(1):12-20 [8115781.001]
  • [Cites] N Engl J Med. 2002 Jun 6;346(23):1781-5 [12050337.001]
  • (PMID = 15913456.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1173094
  •  go-up   go-down


9. Hotokezaka M, Jimi S, Hidaka H, Ikeda T, Uchiyama S, Nakashima S, Tsuchiya K, Chijiiwa K: Factors influencing outcome after surgery for stage IV colorectal cancer. Surg Today; 2008;38(9):784-9
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors influencing outcome after surgery for stage IV colorectal cancer.
  • PURPOSE: According to the classification system of the Japanese Society for Cancer of the Colon and Rectum, Stage IV colorectal cancer is characterized by distant metastasis, which is defined by four factors: liver metastasis (H factor), metastasis to organs other than the liver (M factor), peritoneal dissemination (P factor), and distant lymph node metastasis (N factor).
  • We conducted this study to investigate the postsurgical prognosis of patients with Stage IV colorectal cancer (CRC), in reference to each of these four factors.
  • METHODS: We analyzed the medical records of 73 patients who underwent surgery for Stage IV CRC at our hospital between 1991 and 2001.
  • RESULTS: Univariate analysis revealed that P0 or P1 CRC (P < 0.001), absence of the M factor (P = 0.024), well or moderately differentiated adenocarcinoma (P < 0.001), resection of the primary tumor (P < 0.001), and curability B surgery (P < 0.0001) were associated with a better prognosis than other types of Stage IV CRC.
  • CONCLUSION: Surgery with curative intent should be considered for patients with Stage IV CRC defined by the P1 factor or H factor.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Colorectal Neoplasms / surgery

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18751942.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


10. Read TE, Fleshman JW, Caushaj PF: Sentinel lymph node mapping for adenocarcinoma of the colon does not improve staging accuracy. Dis Colon Rectum; 2005 Jan;48(1):80-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel lymph node mapping for adenocarcinoma of the colon does not improve staging accuracy.
  • PURPOSE: This study was designed to: determine the efficacy of sentinel lymph node mapping in patients with intraperitoneal colon cancer; and create an algorithm to predict potential survival benefit by using best-case estimates in favor of sentinel node mapping and lymph node ultraprocessing techniques.
  • METHODS: Forty-one patients with intraperitoneal colon cancer undergoing colectomy with curative intent were studied prospectively.
  • After mobilization of the colon and mesentery, 1 to 2 ml of isosulfan blue dye was injected subserosally around the tumor.
  • Stage of disease in the remaining 38 patients was: I, n = 10 (26 percent); II, n = 15 (39 percent); III, n = 11 (29 percent); IV, n = 2 (5 percent).
  • To create a survival benefit algorithm, we assumed the following: combined fraction of Stage I and II disease (0.5); fraction understaged by bivalving and hematoxylin and eosin staining that would have occult positive nodes by more sophisticated analysis (0.15); fraction of occult positive nodes detected by sentinel node mapping (0.9); and survival benefit from chemotherapy (0.33).
  • CONCLUSIONS: Sentinel node mapping with isosulfan blue dye and routine processing of retrieved nodes does not improve staging accuracy in patients with intraperitoneal colon cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Algorithms. Colonic Neoplasms / pathology. Neoplasm Staging / methods. Sentinel Lymph Node Biopsy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15690662.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Armbrust T, Sobotta M, Füzesi L, Grabbe E, Ramadori G: Chemotherapy-induced suppression to adenoma or complete suppression of the primary in patients with stage IV colorectal cancer: report of four cases. Eur J Gastroenterol Hepatol; 2007 Nov;19(11):988-94
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy-induced suppression to adenoma or complete suppression of the primary in patients with stage IV colorectal cancer: report of four cases.
  • BACKGROUND: Although modern chemotherapy of stage IV advanced colorectal cancer (CRC) has impressively improved overall survival, the response of the primary tumor has not been studied because surgical resection of the primary continues to be the standard procedure in stage IV CRC.
  • AIM: Long-term follow-up of the primary in patients with stage IV CRC under chemotherapy.
  • METHODS AND RESULTS: Here we report on the histological changes in the primary tumor in four patients suffering from stage IV CRC.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Colorectal Neoplasms / drug therapy
  • [MeSH-minor] Adenoma / drug therapy. Adenoma / pathology. Aged. Colon / pathology. Colonic Polyps / drug therapy. Colonic Polyps / pathology. Colonic Polyps / surgery. Colonoscopy. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Liver Neoplasms / drug therapy. Liver Neoplasms / pathology. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Remission Induction. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18049169.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


12. Song W, He YL, Cai SR, Zhang CH, Chen CQ, Peng JJ, Zhan WH: [Clinical features of colorectal mucinous adenocarcinoma]. Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Sep;12(5):487-90
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features of colorectal mucinous adenocarcinoma].
  • OBJECTIVE: To investigate the clinicopathological characteristics and prognosis of colorectal mucinous adenocarcinoma (MAC) and non-mucinous adenocarcinoma (NMAC).
  • METHODS: Clinical data of 2089 cases with colorectal cancer from 1994 to 2007 in our hospital, including 169 patients diagnosed as mucinous adenocarcinoma were analyzed retrospectively.
  • The rates of tumor location in colon (97 cases,57.4% vs 814 cases, 44.3%, in MAC and NMAC) were significantly different (P<0.01).
  • The rate of radical resection (86.4% vs 91.5%), hepatic metastasis (5.3% vs 8.5%) and local recurrence had no significant difference between patients with mucinous and non-mucinous adenocarcinoma (P>0.05).
  • In comparison to NMAC patients, MAC patients were worse in long-term overall survival, the survival of receiving radical resection and of TNM stage (II+III) group (P<0.01).
  • Survivals were not significantly different in TNM stage I and IV groups between mucinous and non-mucinous adenocarcinoma (P>0.05).
  • CONCLUSIONS: Colorectal mucinous adenocarcinoma patients have worse outcome in comparison to non-mucinous adenocarcinoma patients.
  • Mucinous adenocarcinoma may have special biological behavior, which is an independent prognostic factor for patients with colorectal cancer.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Colorectal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19742341.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


13. Cellini C, Hunt SR, Fleshman JW, Birnbaum EH, Bierhals AJ, Mutch MG: Stage IV rectal cancer with liver metastases: is there a benefit to resection of the primary tumor? World J Surg; 2010 May;34(5):1102-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage IV rectal cancer with liver metastases: is there a benefit to resection of the primary tumor?
  • BACKGROUND: Resection of primary and liver lesions is the optimal management of Stage IV rectal cancer with liver metastases.
  • We compared survival outcomes in patients with Stage IV rectal cancer with liver metastases undergoing staged or synchronous resection with those undergoing primary rectal resection only or no resection at all.
  • [MeSH-major] Adenocarcinoma / surgery. Liver Neoplasms / surgery. Rectal Neoplasms / surgery

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20177683.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Wick MR, Vitsky JL, Ritter JH, Swanson PE, Mills SE: Sporadic medullary carcinoma of the colon: a clinicopathologic comparison with nonhereditary poorly differentiated enteric-type adenocarcinoma and neuroendocrine colorectal carcinoma. Am J Clin Pathol; 2005 Jan;123(1):56-65
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sporadic medullary carcinoma of the colon: a clinicopathologic comparison with nonhereditary poorly differentiated enteric-type adenocarcinoma and neuroendocrine colorectal carcinoma.
  • MCRCs were significantly more common in the ascending colon than were ECRCs, but there was no significant dissimilarity to NECs.
  • Despite an infiltrative growth pattern, MCRC was less likely than ECRC to manifest with stage III or IV disease, but there was no stage-related difference from NECs.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Medullary / pathology. Carcinoma, Neuroendocrine / pathology. Colorectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15762280.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Arfa N, Hamdani I, Gharbi L, Ben Abid S, Ghariani B, Mannai S, Mestiri H, Khalfallah MT, Mzabi SR: [Survival and prognostic factors of colorectal adenocarcinoma: analytic multifactor review of 150 cases]. Ann Chir; 2006 Feb;131(2):104-11
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Survival and prognostic factors of colorectal adenocarcinoma: analytic multifactor review of 150 cases].
  • [Transliterated title] Survie et facteurs pronostiques des adénocarcinomes colorectaux: étude analytique uni- et multifactorielle de 150 cas.
  • This study attempts to observe the survival of colorectal adenocarcinoma and to find prognostic factors and other variables potentially associated with outcome of colorectal adenocarcinoma.
  • MATERIAL AND METHODS: It's a retrospective study based on 150 patients with colorectal adenocarcinoma from 1990 to 2002.
  • 84 patients had colon adenocarcinoma and 66 patients had rectal adenocarcinoma.
  • In histological exam the adenocarcinoma was well differenced in 69 cases (46%), and undifferentiated in 17 cases (18, 3%).
  • There were 6 patients (4%) Dukes stage I TNM, 61 stage II (40, 7%), 51 stage III TNM (34%) and 32 patients stage IV TNM (34%).
  • All patients had surgical curative resection associated with adjuvant chemotherapy in 60 cases of colon adenocarcinoma and preoperative radiotherapy in 33 cases of rectal adenocarcinoma.
  • In addition to the clinical factors, we found of significant prognostic value undifferentiated adenocarcinoma and an elevated value of serum carcinoembryonic antigen>5 ng/ml.
  • [MeSH-major] Adenocarcinoma / mortality. Colorectal Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16443189.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


16. Perazzo F, Denninghoff V, Pasccon G, Pallotta MG, Tatangelo M, Cuartero V, Kirchuck R, Chacón M, Gennari L, Vera K, Avagnina A: Preliminary report of the mutation status of KRAS and BRAF-V600E in an Argentinean population of primary colorectal tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e22183

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary tumor site was 21.9% (32) right colon, 5.5% (8) transverse colon, 45.2% (66) left colon and 27.4%(40) rectal cancer.
  • Adenocarcinoma was the unique histotype and mucinous differentiation was observed in 14.7% (21).
  • The Pathological Stage at diagnosis was Stage I 3.42% (5), II 24% (35), III 33.6% (49) and IV 39% (57).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963599.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Kim J, Chae Y, Sohn S, Kang B, Lee S, Lim K, Choi G, Baek J: -93G&gt;A polymorphism of hMLH1 associated with prognosis for patients with colorectal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4039

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Three hundred and ninety- seven consecutive patients with curatively resected colorectal adenocarcinoma were enrolled in the present study.
  • RESULTS: The median age of the patients was 63 years (range, 21-85), and 218 (54.9%) patients had colon cancer and 179 (45.1%) patients rectal cancer.
  • Pathologic stages after surgery were as follows: stage 0/I (n=86, 21.7%), stage II (n=146, 36.8%), stage III (n=145, 36.5%), and stage IV (n=20, 5.0%).
  • Multivariate survival analysis including stage, differentiation, age, and CEA level showed that the survival for the patients with the -93AA genotype of hMLH1 was worse than for the patients with the combined -93GG and GA genotype (overall survival: hazard ratio [HR]=2.953, 95% Confidential Interval [CI], 1.273-6.850, P=0.012; disease-free survival: HR=2.299, 95% CI, 1.417-3.730, P=0.001), whereas the other polymorphisms were not associated with survival.
  • Accordingly, in addition to the pathologic stage, the analysis of -93G>A polymorphism of hMLH1 can help identify patient subgroups at high risk of a poor disease outcome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961540.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Gervaz P, Rubbia-Brandt L, Andres A, Majno P, Roth A, Morel P, Mentha G: Neoadjuvant chemotherapy in patients with stage IV colorectal cancer: a comparison of histological response in liver metastases, primary tumors, and regional lymph nodes. Ann Surg Oncol; 2010 Oct;17(10):2714-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy in patients with stage IV colorectal cancer: a comparison of histological response in liver metastases, primary tumors, and regional lymph nodes.
  • METHODS: Twenty-nine patients with stage IV CRC received a combination of oxaliplatin, irinotecan, 5-fluorouracil, and leucovorin (OCFL) for 3-4 months.
  • Primary tumor location was right colon (n = 5), left colon (n = 7), and rectum (n = 17 patients).
  • CONCLUSIONS: In patients with stage IV colorectal cancer, liver metastases exhibit a better histological response than primary tumors to OCFL neoadjuvant chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Lymph Nodes / drug effects. Neoadjuvant Therapy

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20405223.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


19. Snaebjörnsson P, Jónasson L, Jónsson T, Möller PH, Theodórs A, Jónasson JG: [Colon cancer in Iceland 1955-2004. Study on epidemiology, histopathology and gender difference]. Laeknabladid; 2009 Jun;95(6):423-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Colon cancer in Iceland 1955-2004. Study on epidemiology, histopathology and gender difference].
  • OBJECTIVE: Colon cancer is the third most common cancer in Iceland.
  • The aim of this study was to analyze the epidemiology and histopathology of colon cancer in Iceland, resection rate and the difference between men and women.
  • MATERIAL AND METHODS: Pathology and autopsy reports for all patients diagnosed with colon cancer between 1955 and 2004 where reviewed.
  • Most tumors were located in the sigmoid colon (35%).
  • Adenocarcinomas where 84% and mucinous adenocarcinoma 7%.
  • Altogether 7% of cases were TNM-stage I, 32% were stage II, 24% stage III, 21% in stage IV and stage was unknown in 16% of cases.
  • CONCLUSION: Incidence of colon cancer increased considerably, mainly for men.
  • Surgical rate and pathology of colon cancer is similar to that reported elsewhere except that there are somewhat fewer cases in TNM-stage I.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma, Mucinous / epidemiology. Colonic Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Laeknabladid. 2009 Jun;95(6):419 [19491405.001]
  • (PMID = 19491407.001).
  • [ISSN] 0023-7213
  • [Journal-full-title] Læknablađiđ
  • [ISO-abbreviation] Laeknabladid
  • [Language] ice
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Iceland
  •  go-up   go-down


20. López-Cano M, Mañas MJ, Hermosilla E, Espín E: Multivisceral resection for colon cancer: analysis of prognostic factors. Dig Surg; 2010 Aug;27(3):238-45

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multivisceral resection for colon cancer: analysis of prognostic factors.
  • BACKGROUND/AIMS: To assess outcome of multivisceral resection in colon cancer patients and to identify predictors of survival.
  • METHODS: One hundred and thirteen consecutive patients with primary locally advanced colon cancer infiltrating adjacent organs undergoing multivisceral resection between 1998 and 2007 were reviewed.
  • The diagnosis was conventional adenocarcinoma in 94 patients.
  • Hematochezia and adjuvant chemotherapy were independent factors of favorable outcome and grade G3 and tumor stage III-IV of poor survival.
  • CONCLUSION: Hematochezia and adjuvant chemotherapy were associated with a better survival, and poorly differentiated tumors and stage IV disease with a poor survival.
  • [MeSH-minor] Abdomen, Acute. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Gastrointestinal Hemorrhage / complications. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Recurrence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20571272.001).
  • [ISSN] 1421-9883
  • [Journal-full-title] Digestive surgery
  • [ISO-abbreviation] Dig Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


21. Chang GJ, Gonzalez RJ, Skibber JM, Eng C, Das P, Rodriguez-Bigas MA: A twenty-year experience with adenocarcinoma of the anal canal. Dis Colon Rectum; 2009 Aug;52(8):1375-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A twenty-year experience with adenocarcinoma of the anal canal.
  • PURPOSE: Adenocarcinoma of the anal canal is a rare malignancy with limited data regarding treatment and outcomes.
  • The purpose of this study is to evaluate disease control and survival outcomes in patients with adenocarcinoma of the anal canal.
  • METHODS: A retrospective consecutive cohort study of all patients in whom adenocarcinoma of the anal canal was diagnosed between 1983 and 2004 was performed.
  • RESULTS: Thirty-four patients were identified; six underwent palliative treatment (Stage IV, n = 4; poor performance, n = 2).
  • CONCLUSION: Combined modality treatment with radical surgical resection improves survival among patients with adenocarcinoma of the anal canal, but a high risk for distant failure emphasizes the need for effective adjuvant therapeutic regimens.
  • [MeSH-major] Adenocarcinoma / epidemiology. Anus Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19617747.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Kato T, Terashima T, Tomida S, Yamaguchi T, Kawamura H, Kimura N, Ohtani H: Cytokeratin 20-positive large cell neuroendocrine carcinoma of the colon. Pathol Int; 2005 Aug;55(8):524-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokeratin 20-positive large cell neuroendocrine carcinoma of the colon.
  • Herein is presented a case of cytokeratin (CK) 20-positive large cell neuroendocrine carcinoma of the colon, in which the tumor was clinically at stage IV and located in the ascending colon.
  • No areas showed differentiation toward adenocarcinoma or squamous cell carcinoma.
  • With these features, the tumor was diagnosed as a large cell neuroendocrine carcinoma of the colon.
  • To the best of the authors' knowledge, the present case is the first CK 20-positive, CK 7-negative colorectal neuroendocrine carcinoma to be described, suggesting a link between colorectal neuroendocrine carcinoma and conventional adenocarcinoma.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15998383.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Intermediate Filament Proteins; 0 / KRT20 protein, human; 0 / Keratin-20
  •  go-up   go-down


23. Nakao K, Tsunoda A, Amagasa H, Suzuki N, Yamazaki K, Kusano M: [A case report of poorly-differentiated adenocarcinoma in sigmoid colon cancer with liver and pulmonary metastasis responding to TS-1 and CPT-11]. Gan To Kagaku Ryoho; 2006 Jan;33(1):109-12
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of poorly-differentiated adenocarcinoma in sigmoid colon cancer with liver and pulmonary metastasis responding to TS-1 and CPT-11].
  • Pathological findings were type 3, 30 x 20 mm, poorly-differentiated adenocarcinoma, se, ly 2, v 2, n 2 (+), ow (-), aw(-), H 3, P 0 (stage IV).
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Sigmoid Neoplasms / drug therapy. Sigmoid Neoplasms / pathology

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16410709.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


24. Yamamoto A, Ishibashi K, Tajima Y, Hatano S, Ishiguro T, Osawa T, Okada N, Kumamoto K, Yokoyama M, Haga N, Ishida H: [Successfully resected an isolated extraperitoneal metastasis of sigmoid colon cancer--a case report]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2644-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successfully resected an isolated extraperitoneal metastasis of sigmoid colon cancer--a case report].
  • We herein report an extremely rare operative case of an isolated extraperitoneal metastasis of colon cancer.
  • A female patient had undergone a sigmoidectomy for ileus due to sigmoid colon cancer when she was 40 years old.
  • Peritoneal metastasis, 5 mm in diameter, was on the sigmoid colon mesentery and she was histologically diagnosed as Stage IV.
  • A histological examination of the tumor revealed a moderately differentiated adenocarcinoma similar to colon cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Ovarian Neoplasms / secondary. Pelvic Neoplasms / secondary. Sigmoid Neoplasms / pathology. Sigmoid Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224666.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


25. Chang GJ, Hu CY, Eng C, Skibber JM, Rodriguez-Bigas MA: Practical application of a calculator for conditional survival in colon cancer. J Clin Oncol; 2009 Dec 10;27(35):5938-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Practical application of a calculator for conditional survival in colon cancer.
  • In this study we performed a contemporary evaluation of conditional survival among colon cancer patients and created a browser-based tool for real-time determination of conditional survival expectancies.
  • PATIENTS AND METHODS: Patients with colon adenocarcinoma diagnosed between 1988 and 2000 were identified from the Surveillance Epidemiology End Results (SEER) registry.
  • Conditional survival estimates were calculated by using the multiplicative law of probability after adjustment for age; sex; ethnicity; grade; and American Joint Commission on Cancer, sixth edition stage.
  • As the time alive after initial treatment increased from 0 to 5 years, significant improvements in CS were observed for patients in all stages except stage I, which was associated with good CS even at diagnosis and which reflected the high likelihood of cure.
  • Notably, adjusted 5-year CS rates improved from 42% to 80% for stage IIIC cancers and from 5% to 48% for stage IV cancers during the first 5 years.
  • CONCLUSION: For patients with colon cancer who survive over time, 5-year, cancer-specific CS improved dramatically, and the greatest improvements were among patients with poorer initial prognoses.
  • [MeSH-major] Adenocarcinoma / mortality. Colonic Neoplasms / mortality. Health Status Indicators

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19805670.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


26. Kim ST, Lee J, Park SH, Park JO, Lim HY, Kang WK, Kim JY, Kim YH, Chang DK, Rhee PL, Kim DS, Yun H, Cho YB, Kim HC, Yun SH, Lee WY, Chun HK, Park YS: Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Cancer Chemother Pharmacol; 2010 Sep;66(4):659-67
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
  • PURPOSE: Colon cancer with DNA mismatch repair (MMR) defects reveals indistinguishable clinical and pathologic aspects, including better prognosis and reduced response to 5-fluorouracil (5-FU)-based chemotherapy.
  • This study investigated the clinical implication of MSI-H/MMR-D and p53 expression in R0-resected colon cancer patients who received adjuvant oxaliplatin/5-FU/leucovorin (FOLFOX) therapy.
  • EXPERIMENTAL DESIGN: We analyzed 135 patients, who had been treated by adjuvant chemotherapy containing 5-FU and oxaliplatin (FOLFOX) after curative resection (R0) for colon adenocarcinoma between May 2004 and November 2007.
  • RESULTS: There were 13 (9.6%) patients with stage II, 108 (80%) with stage III, and 14 (10.4%) with stage IV.
  • Fourteen patients with stage IV (10.3%) had metastases to liver only, all of whom underwent complete metastasectomy for liver metastases.
  • MMR status was not significantly associated with DFS (P = 0.56) or OS (P = 0.61) in patients with colon cancer (n = 135) receiving adjuvant FOLFOX.
  • CONCLUSION: The MMR status or p53 positivity was not significantly associated with outcomes to FOLFOX as adjuvant chemotherapy in colon cancer patients with R0 resection.
  • Adding oxaliplatin in adjuvant chemotherapy may overcome negative impact of 5-FU on colon cancers with MSI-H/MMR-D.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Colonic Neoplasms / genetics. Microsatellite Instability / drug effects

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20033812.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Genetic Markers; 0 / Organoplatinum Compounds; 0 / Tumor Suppressor Protein p53; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


27. Mamiya N, Kono T, Mamiya K, Satomi M, Chisato N, Ebisawa Y: [A case of neurotoxicity reduced with goshajinkigan in modified FOLFOX6 chemotherapy for advanced colon cancer]. Gan To Kagaku Ryoho; 2007 Aug;34(8):1295-7
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of neurotoxicity reduced with goshajinkigan in modified FOLFOX6 chemotherapy for advanced colon cancer].
  • We have applied goshajinkigan (TJ 107) for a case of advanced colon cancer with mFOLFOX 6, and experienced a reduction in numbness, the adverse effect of LOHP.
  • A 57-year-old woman with descending colon cancer (H 1, P 3, Stage IV) underwent hemicolectomy D 2, rt.colectomy, bilateral oophorectomy, cholecystectomy and transverse colonostomy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Drugs, Chinese Herbal / administration & dosage. Neurotoxicity Syndromes / prevention & control

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17687217.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / Organoplatinum Compounds; 0 / gosha-jinki-gan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


28. Handa R, Kato T, Miyake Y, Oshima K, Oshima S, Iijima S, Yamamoto H, Kurokawa E, Kikkawa N: [A long term survival case of advanced colon cancer with adjacent organ involvement and multiple liver metastases]. Gan To Kagaku Ryoho; 2006 Nov;33(12):1795-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A long term survival case of advanced colon cancer with adjacent organ involvement and multiple liver metastases].
  • We report a long-term survival case of advanced colon cancer with adjacent organ involvement and multiple liver metastases.
  • An advanced colon cancer of the cecum was found with a colonoscopy.
  • Histopathologically, it was a moderately differentiated adenocarcinoma with a biopsy examination.
  • Abdominal CT showed advanced colon cancer with adjacent organ involvement and multiple liver metastases.
  • He received right hemi-colon resection and right hepatic lobectomy.
  • Usually the prognoses of Stage IV colorectal cancer patients are very unpleasant.
  • Even thougn a few patients with Stage IV colorectal cancer can be a long-term survivor after multiple operations, we need to consider carefully the indication of the operation and QOL for a Stage IV colorectal cancer patient.
  • [MeSH-major] Adenocarcinoma / secondary. Cecal Neoplasms / pathology. Liver Neoplasms / secondary

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17212110.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] U3P01618RT / Fluorouracil
  •  go-up   go-down


29. Henry LR, Lee HO, Lee JS, Klein-Szanto A, Watts P, Ross EA, Chen WT, Cheng JD: Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res; 2007 Mar 15;13(6):1736-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical implications of fibroblast activation protein in patients with colon cancer.
  • PURPOSE: Human fibroblast activation protein (FAP)/seprase is a 97-kDa surface glycoprotein expressed on tumor associated fibroblasts in the majority of epithelial cancers including colon adenocarcinomas.
  • The primary objective of this study was to evaluate the clinical significance of stromal FAP in human colon cancers by immunohistochemisty.
  • EXPERIMENTAL DESIGN: Sections of paraffin-embedded resected primary human colon cancer specimens from 1996 through 2001 within the Fox Chase Cancer Center tumor bank were stained with D8 antibody directed against FAP/seprase.
  • RESULTS: One hundred thirty-eight patients with resected specimens were available for study (mean follow-up, 1,050 days) with 6 (4%) stage I, 52 (38%) stage II, 43 (31%) stage III, and 37 (27%) stage IV patients.
  • Stromal FAP was found to correlate inversely with tumor stage (semiquantitative, P = 0.01; intensity, P = 0.009) and with tumor size of the tumor xenograft model (correlation coefficient, -0.61; P = 0.047), suggesting that stromal FAP may have a greater role in the early development of tumors.
  • CONCLUSION: Our data indicate that patients whose colon tumors have high levels of stromal FAP are more likely to have aggressive disease progression and potential development of metastases or recurrence.
  • It also suggests that the effects of FAP inhibition should be investigated in earlier-stage tumors, given its high levels and potential effect earlier in the course of the disease.
  • [MeSH-major] Adenocarcinoma / genetics. Antigens, Neoplasm / genetics. Biomarkers, Tumor / genetics. Colonic Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Serine Endopeptidases / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17363526.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA006927; United States / NCI NIH HHS / CA / CA09035; United States / NCI NIH HHS / CA / CA090468; United States / NCI NIH HHS / CA / CA103991; United States / PHS HHS / / W81XWH-04-1-0709
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Membrane Proteins; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / fibroblast activation protein alpha; EC 3.4.24.- / Gelatinases
  •  go-up   go-down


30. Sjo OH, Larsen S, Lunde OC, Nesbakken A: Short term outcome after emergency and elective surgery for colon cancer. Colorectal Dis; 2009 Sep;11(7):733-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short term outcome after emergency and elective surgery for colon cancer.
  • OBJECTIVE: Emergency presentation of colon cancer is common and associated with high mortality and morbidity following surgical treatment.
  • METHOD: All patients with adenocarcinoma of the colon diagnosed between 1993 and 2007 were registered prospectively.
  • Multivariate analyses demonstrated that emergency operation, increasing age, advanced tumour stage and ASA class IV were independent risk factors for postoperative mortality.
  • CONCLUSION: Emergency operation for colon cancer was associated with high rates of complications and mortality, indicating that immediate surgery should be avoided if possible.
  • [MeSH-major] Adenocarcinoma / surgery. Colectomy / adverse effects. Colonic Neoplasms / surgery. Colostomy / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18624817.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


31. Takahashi S, Iiai T, Shimada Y, Kobayashi Y, Suda K, Iwaya A, Maruyama S, Tani T, Hatakeyama K: [A long-term survival case of far-advanced colon cancer with Virchow's lymph node and lung metastasis that responded to multidisciplinary therapy]. Gan To Kagaku Ryoho; 2009 Jan;36(1):127-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A long-term survival case of far-advanced colon cancer with Virchow's lymph node and lung metastasis that responded to multidisciplinary therapy].
  • Under a diagnosis of advanced cecal colon cancer with metastasis to Virchow's and paraaortic lymph nodes and lungs, a laparoscopic-assisted ileocecal resection with D2 lymph node dissection was performed.
  • Histological examination of the resected specimens revealed moderately-differentiated adenocarcinoma which had invaded the terminal ileum.
  • The lesion was judged to be SI(ileum), N2, H0, P0, M1(Virchow's lymph node, No. 216, lungs), Stage IV.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19151578.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


32. Hiraki M, Yakushiji H, Hashiguchi K, Harada S: [Combination chemotherapy with oral TS-1 and low-dose CPT-11 by hepatic arterial infusion for multiple hepatic metastases from colon cancer--a case report]. Gan To Kagaku Ryoho; 2005 Jul;32(7):1055-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combination chemotherapy with oral TS-1 and low-dose CPT-11 by hepatic arterial infusion for multiple hepatic metastases from colon cancer--a case report].
  • A 53-year-old man was diagnosed with multiple hepatic metastases from advanced colon cancer (Stage IV).
  • The patient underwent partial resection of the colon and catheter insertion into hepatic artery for arterial infusion in November 2003.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Colonic Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary

  • Genetic Alliance. consumer health - Oral cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16044973.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


33. Kang H, O'Connell JB, Maggard MA, Sack J, Ko CY: A 10-year outcomes evaluation of mucinous and signet-ring cell carcinoma of the colon and rectum. Dis Colon Rectum; 2005 Jun;48(6):1161-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A 10-year outcomes evaluation of mucinous and signet-ring cell carcinoma of the colon and rectum.
  • This study used a national cancer registry to analyze the epidemiology and survival outcomes of these two subtypes of colorectal cancer compared with adenocarcinoma tumors.
  • METHODS: All patients diagnosed with mucinous (n = 16,991), signet-ring cell (n = 1,522), or adenocarcinoma (n = 146,115) colorectal cancer in the Surveillance, Epidemiology, and End Results database (1991-2000) were evaluated.
  • Analyses were performed to obtain age-adjusted incidence rates, stage at presentation, tumor grade, and five-year relative survival for each subtype.
  • Incidence rates per 100,000 persons were: mucinous, 5.5; signet-ring cell, 0.6; and adenocarcinoma 46.6.
  • The annual percent change during ten years was stable for mucinous, increased for signet-ring cell (4.8 percent; P < 0.05), and decreased for adenocarcinoma (-1.1 percent; P < 0.05).
  • Fewer mucinous (18 percent) and signet-ring cell (21 percent) tumors were located in the rectum compared with adenocarcinoma (29 percent).
  • Signet-ring cell presented at later stage (III/IV, 80.9 percent) more often than mucinous (52.8 percent) and adenocarcinoma (49.5 percent), and also had worse tumor grade (high grade: signet-ring cell, 73.5 percent; mucinous, 20.9 percent; adenocarcinoma, 17.5 percent).
  • Relative five-year survival was worse for signet-ring cell than mucinous or adenocarcinoma.
  • Although the incidence of colorectal adenocarcinoma is decreasing in the United States, mucinous and signet-ring cell subtypes are stable and increasing, respectively.
  • [MeSH-major] Adenocarcinoma, Mucinous / epidemiology. Carcinoma, Signet Ring Cell / epidemiology. Colonic Neoplasms / epidemiology. Rectal Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868237.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


34. Sato Y, Takayama T, Nikaido T, Wada Y, Sagawa T, Abe S, Sato T, Iyama S, Murase K, Araki H, Sato Y, Kato J, Niitsu Y, Chiba H: Report of an autopsy case of colon cancer with amyotrophic lateral sclerosis. Nihon Shokakibyo Gakkai Zasshi; 2007 Sep;104(9):1365-70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Report of an autopsy case of colon cancer with amyotrophic lateral sclerosis.
  • A 60-year-old man with rectal cancer (Stage IV) having multiple lung, liver and para-aortic lymph node metastases underwent anterior resection of the rectum as palliative surgery.
  • [MeSH-major] Adenocarcinoma / secondary. Amyotrophic Lateral Sclerosis / etiology. Colonic Neoplasms / pathology

  • Genetic Alliance. consumer health - Amyotrophic Lateral Sclerosis.
  • MedlinePlus Health Information. consumer health - Amyotrophic Lateral Sclerosis.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17827908.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; IFL protocol
  •  go-up   go-down


35. Chang SC, Lin JK, Lin TC, Liang WY: Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma. Int J Oncol; 2005 Jan;26(1):65-75
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma.
  • Of these, 20 were stage I (12%), 54 stage II (32.3%), 58 stage III (34.7%), and 35 stage IV (21%).
  • Genetic p53 alterations were associated with advanced tumor stage and tumor differentiation.
  • Of 132 potentially cured patients, 3-year disease-free survival (DFS) was affected by: advanced TNM stage (I, II, III: 90%, 84%, and 41%), genetic p53 alteration (89% vs. 43%), intratumoral p53 accumulation (71% vs. 56%), and preoperative CEA level >5 ng/ml (74% vs. 58%).
  • In multivariate analysis, genetic alteration of p53 was the most significant independent prognostic factor [hazard ratio (HR) = 6.09; 95% confidence interval (CI): 2.45-15.11], followed by advanced tumor stage (HR = 3.93; 95% CI: 2.14-7.23), and preoperative CEA >5 ng/ml (HR = 1.98; 95% CI: 1.12-3.17).
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / genetics. Colorectal Neoplasms / diagnosis. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15586226.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


36. Pande R, Sunga A, Levea C, Wilding GE, Bshara W, Reid M, Fakih MG: Significance of signet-ring cells in patients with colorectal cancer. Dis Colon Rectum; 2008 Jan;51(1):50-5
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The outcome of patients with a component of signet-ring cells was compared to all patients with mucinous adenocarcinoma (defined as adenocarcinomas with > or = 50 percent mucin) to all patients with adenocarcinomas with a component of mucin (defined as adenocarcinomas with < 50 percent mucin) and to 100 randomly selected patients with adenocarcinomas lacking mucin or signet-ring cells.
  • RESULTS: Five percent of patients had a component of signet-ring cells, 3 percent had mucinous adenocarcinoma, 9 percent had a component of mucinous adenocarcinoma, and 83 percent had adenocarcinoma lacking mucinous or signet components.
  • The pattern of metastases of patients with adenocarcinoma without mucinous or signet components predominantly involved the liver/lungs and rarely the peritoneum/ovaries (12.5 percent).
  • The pattern of metastases for patients with a component of mucinous adenocarcinoma was intermediate between mucinous adenocarcinoma and adenocarcinoma without mucin or signet-ring component.
  • No differences in survival in Stage IV patients were seen among the four subgroups.
  • CONCLUSIONS: Patients with a component of signet-ring cells cancers, similar to mucinous adenocarcinoma, have a predisposition to metastasize to the peritoneum/ovaries.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Signet Ring Cell / pathology. Colorectal Neoplasms / pathology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18030531.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


37. Silvéra L, Galula G, Tiret E, Louvet C, Leroux JL, Trutt B: Assessment of management practices for colonic cancer in the Paris metropolitan area in 2002. Gastroenterol Clin Biol; 2006 Jun-Jul;30(6-7):852-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To assess the management of patients aged 18 years or older with colonic adenocarcinoma (including the rectosigmoid junction), compared with French guidelines (ANAES and SOR).
  • METHODS: This retrospective study carried out in 2003 by the Ile-de-France regional union of health insurance funds from hospital discharge and operative and pathology reports of patients exempted from copayment between April 2001 and March 2002.
  • 37.7% of stage II patients had chemotherapy while 10.8% of stage III and 9.8% of stage IV patients did not.
  • CONCLUSION: Implementation of guidelines for the management of colon cancer can be improved, notably regarding pathologic analysis and indications of chemotherapy.
  • [MeSH-major] Adenocarcinoma / therapy. Colonic Neoplasms / therapy
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Colon / pathology. Data Collection. Data Interpretation, Statistical. Female. Guideline Adherence. Humans. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Neoplasms, Multiple Primary / therapy. Paris. Practice Guidelines as Topic. Retrospective Studies. Surveys and Questionnaires

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16885869.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] France
  •  go-up   go-down


38. Brozovich M, Read TE, Salgado J, Akbari RP, McCormick JT, Caushaj PF: Laparoscopic colectomy for apparently benign colorectal neoplasia: A word of caution. Surg Endosc; 2008 Feb;22(2):506-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (1) a substantial fraction of patients undergoing laparoscopic colectomy for apparently benign colorectal neoplasia will have adenocarcinoma on final pathology; and (2) in our practice, we perform an adequate laparoscopic oncological resection for apparently benign polyps as evidenced by margin status and nodal retrieval.
  • Invasive adenocarcinoma was found on histological analysis of the colectomy specimen in 14 out of 63 cases (22%), standard error of the proportion 0.052.
  • Staging of the 14 cancers were I (n = 6, 43%), II (n = 3, 21%), III ( = 4, 29%), and IV (n = 1, 7%).
  • Neither dysplasia on endoscopic biopsy nor lesion diameter was predictive of adenocarcinoma.
  • Eight out of 23 (35%) patients with dysplasia on endoscopic biopsy had adenocarcinoma on final pathology versus 6/40 (15%) with no dysplasia (p = 0.114, Fisher's exact test).
  • CONCLUSION: A substantial fraction of endoscopically unresectable colorectal neoplasms with benign histology on initial biopsy will harbor invasive adenocarcinoma, some of advanced stage.
  • [MeSH-major] Adenocarcinoma / surgery. Colectomy / methods. Colonic Polyps / surgery. Colorectal Neoplasms / surgery. Laparoscopy

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17704872.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


39. Fujita S, Yamamoto S, Akasu T, Moriya Y, Taniguchi H, Shimoda T: Quantification of CD10 mRNA in colorectal cancer and relationship between mRNA expression and liver metastasis. Anticancer Res; 2007 Sep-Oct;27(5A):3307-11
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • TIN was higher in colon, pN1/pN2, stage III and IV, and well- or moderately-differentiated adenocarcinoma than in rectum, pNO, stage I and II, and poorly-differentiated or mucinous adenocarcinoma, respectively.
  • Although CD10 mRNA was associated with invasion depth, lymph node status and TNM stage, it was not associated with prognosis.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / immunology. Adenocarcinoma / pathology. Adenocarcinoma / secondary. Female. Humans. Male. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17970075.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


40. Secen S, Moljević N, Vuković M, Somer L: [Histopathological finding as a prognostic factor of the surgical treatment outcome in colorectal cancer]. Vojnosanit Pregl; 2010 Aug;67(8):638-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIM: Adenocarcinomas of the colon are the most common malignant colorectal tumors.
  • These factors comprise Astler-Coller-Dukes stage D (revealed in 77.78% patients died), stage IV according TNM classification (T1-4, N0-2, M1), histological structure (poorly diferentiated adenocarcinoma in 85.2% patents died) and type of tumor (mucynous adenocarcinoma was more often present in died, 77.78%).
  • Since phi = 0.000 for four risk factors were formed using discriminant analysus, it was proved their significant influence on the outcome of surgical treatment Discriminant coefficient showed that the greatest influence on surgical treatment were registred in patients with tumor of Astler-Coller-Dukes stage D (0.255), poorly differentiated adenocarcinoma (histological structure) (0.139), mucynous adenocarcinoma (type of tumor) (0.074) and stage IV according to the TNM classification (T1-4, N0-2, M1) (0.39).
  • Patients with pathohistological finding of Astler-Coller-Dukes stage D, stage IV according to the TNM classification (T1-4, N0-2, M1) and poorly differentiated adenocarcioma have statistically highly significant mortality during the perioperative course of the disease.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20845666.001).
  • [ISSN] 0042-8450
  • [Journal-full-title] Vojnosanitetski pregled
  • [ISO-abbreviation] Vojnosanit Pregl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


41. Nash GM, Gimbel M, Cohen AM, Zeng ZS, Ndubuisi MI, Nathanson DR, Ott J, Barany F, Paty PB: KRAS mutation and microsatellite instability: two genetic markers of early tumor development that influence the prognosis of colorectal cancer. Ann Surg Oncol; 2010 Feb;17(2):416-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: MSI and KRAS mutation status were assessed in 532 primary adenocarcinomas (stage I-IV) from patients treated by colon resection.
  • MSI was more common in early-stage disease (I, 15%; II, 21%; III, 10%; IV, 2%; P = 0.0001).
  • Prevalence of KRAS mutation did not vary with stage (I, 36%; II, 34%; III, 35%; IV, 40%; P = ns).
  • Using Cox regression analysis MSI, KRAS mutation, and stage were strong independent predictors of survival in the entire patient population.
  • A high-mortality group with MSS/KRAS-mutant tumors was identified within the stage I and II cohort.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19813061.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA065930; United States / NCI NIH HHS / CA / 2 P01 CA65930-05A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ NIHMS674393; NLM/ PMC4380015
  •  go-up   go-down


42. Li SY, Liang ZJ, Yuan SJ, Yu B, Chen G, Zuo FY, Bai X, Chen G, Wei XJ, Xu YS, Cui W: [Clinical experience of 371 cases of sphincter-preservation with telescopic anastomosis after radical excision for low-middle rectal cancer]. Zhonghua Wei Chang Wai Ke Za Zhi; 2010 Apr;13(4):263-5
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the clinical efficacy, feasibility and safety of sphincter-preservation with telescopic anastomosis of colon and rectal mucosa in low-middle rectal cancer.
  • On histopathology, there were 361 adenocarcinomas, including 138 well-differentiated, 201 moderately differentiated, 11 poorly differentiated, 11 mucinous adenocarcinoma, and 10 adenomas with neoplastic changes.
  • According to the Duke's stage classification, 120 were TNM stage I, 222 stage II, 26 stage III, and 3 stage IV.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Anastomosis, Surgical / methods. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20422480.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  •  go-up   go-down


43. Greenblatt DY, Weber SM, O'Connor ES, LoConte NK, Liou JI, Smith MA: Readmission after colectomy for cancer predicts one-year mortality. Ann Surg; 2010 Apr;251(4):659-69
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Medicare beneficiaries who underwent colectomy for stage I to III colon adenocarcinoma from 1992 to 2002 were identified from the Surveillance, Epidemiology, and End Results-Medicare database.
  • Early readmission is therefore an important quality-of-care indicator for colon cancer surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Intern Med. 2000 Apr 24;160(8):1074-81 [10789599.001]
  • [Cites] N Engl J Med. 2009 Apr 2;360(14):1418-28 [19339721.001]
  • [Cites] Health Care Financ Rev. 2000 Spring;21(3):7-28 [11481769.001]
  • [Cites] Dis Colon Rectum. 2001 Jul;44(7):942-6 [11496073.001]
  • [Cites] Br J Surg. 2001 Nov;88(11):1533-8 [11683754.001]
  • [Cites] Ann Thorac Surg. 2001 Dec;72(6):1855-9; discussion 1859-60 [11789760.001]
  • [Cites] J Am Geriatr Soc. 2001 Nov;49(11):1561-4 [11890600.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-3-18 [12187163.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-62-8 [12187170.001]
  • [Cites] Dis Colon Rectum. 2003 Apr;46(4):503-9 [12682545.001]
  • [Cites] Hepatogastroenterology. 2003 Mar-Apr;50(50):432-7 [12749241.001]
  • [Cites] J Surg Oncol. 2003 Jun;83(2):68-78; discussion 78-9 [12772198.001]
  • [Cites] Dis Colon Rectum. 2003 Jul;46(7):851-9 [12847356.001]
  • [Cites] Ann Surg. 2003 Aug;238(2):161-7 [12894006.001]
  • [Cites] JAMA. 2003 Aug 13;290(6):773-80 [12915430.001]
  • [Cites] Ann Surg Oncol. 2003 Nov;10(9):1112-7 [14597452.001]
  • [Cites] Br J Surg. 2003 Dec;90(12):1497-504 [14648727.001]
  • [Cites] Dis Colon Rectum. 2004 Mar;47(3):271-7; discussion 277-8 [14991487.001]
  • [Cites] J Am Coll Surg. 2004 Jun;198(6):877-83 [15194068.001]
  • [Cites] J Am Coll Surg. 2004 Nov;199(5):675-9 [15501105.001]
  • [Cites] Br J Prev Soc Med. 1965 Oct;19(4):182-91 [5845379.001]
  • [Cites] Am J Med. 1991 Jun;90(6):667-74 [2042681.001]
  • [Cites] Med Care. 1993 Aug;31(8):732-48 [8336512.001]
  • [Cites] Conn Med. 1995 May;59(5):263-70 [7600797.001]
  • [Cites] Health Serv Res. 1995 Aug;30(3):489-506 [7649753.001]
  • [Cites] J Qual Clin Pract. 1995 Dec;15(4):211-20 [8719060.001]
  • [Cites] Med Care. 1997 Oct;35(10):1044-59 [9338530.001]
  • [Cites] J Am Coll Surg. 1998 May;186(5):501-6 [9583689.001]
  • [Cites] Ann Surg. 2005 Mar;241(3):416-23 [15729063.001]
  • [Cites] Surg Endosc. 2004 Oct;18(10):1463-8 [15791370.001]
  • [Cites] Dis Colon Rectum. 1999 Nov;42(11):1381-7 [10566524.001]
  • [Cites] J Epidemiol Community Health. 2005 Jun;59(6):506-11 [15911648.001]
  • [Cites] Cancer. 2005 Aug 1;104(3):629-39 [15983985.001]
  • [Cites] Br J Surg. 2005 Nov;92(11):1354-62 [16237744.001]
  • [Cites] J Gastrointest Surg. 2006 Nov;10(9):1243-52; discussion 1252-3 [17114011.001]
  • [Cites] Ann Surg. 2007 Jan;245(1):73-9 [17197968.001]
  • [Cites] Arch Intern Med. 2007 Feb 12;167(3):258-64 [17296881.001]
  • [Cites] Am J Manag Care. 2007 Mar;13(3):157-64 [17335359.001]
  • [Cites] J Am Geriatr Soc. 2007 Mar;55(3):365-73 [17341238.001]
  • [Cites] Curr Probl Cancer. 2007 May-Jun;31(3):123-33 [17543944.001]
  • [Cites] Br J Surg. 2007 Jul;94(7):890-3 [17330930.001]
  • [Cites] Dis Colon Rectum. 2007 Sep;50(9):1316-23 [17665252.001]
  • [Cites] Cancer Biomark. 2007;3(6):301-13 [18048968.001]
  • [Cites] World J Surg. 2007 Dec;31(12):2430-5 [18246608.001]
  • [Cites] Cancer. 2008 Feb 15;112(4):900-8 [18181101.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Ann Surg. 2000 Jul;232(1):51-7 [10862195.001]
  • (PMID = 20224370.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / PC / N02-PC-15105; United States / PHS HHS / / U55/CCR921930 - 02; None / None / / UL1 RR025011-01; United States / NCI NIH HHS / PC / N01-PC-35139; United States / NCRR NIH HHS / RR / UL1 RR025011-01; United States / NCI NIH HHS / CA / P30 CA014520-34; United States / NCI NIH HHS / CA / P30 CA014520; United States / NCI NIH HHS / PC / N02 PC015105; United States / NCRR NIH HHS / RR / UL1 RR025011; United States / NCRR NIH HHS / RR / 1UL1RR025011; None / None / / P30 CA014520-34; United States / NCI NIH HHS / CA / N01PC35136; United States / NCI NIH HHS / CA / N01PC35139; United States / NCI NIH HHS / PC / N01-PC-35136
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS230999; NLM/ PMC2951007
  •  go-up   go-down


44. Selvindos PB, Ho YH: Multimedia article. Laparoscopic ultralow anterior resection with colonic J-pouch-anal anastomosis. Dis Colon Rectum; 2008 Nov;51(11):1710-1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with adenocarcinoma underwent preoperative endorectal ultrasound to individualize for neoadjuvant chemoradiotherapy, based on local extent and lymph nodes seen.
  • The indications were adenocarcinoma (n = 51), squamous-cell carcinoma of rectum (n = 1), dermoid tumor of mesorectum (n = 1), large villous adenoma (n = 1), and carcinoid with local lymph node metastases (n = 1).
  • The histologic grading or the adenocarcinoma patients were: Stage I, n = 14; Stage II, n = 23; Stage III, n = 11; Stage IV, n = 3.
  • At a median follow-up of 14 (2-33) months, none of the adenocarcinoma patients who had undergone curative resection had recurrences.
  • Four other patients had smaller pelvic collections that resolved with antibiotics; pelvic collections were associated with advanced stage of cancer (P = 0.047).
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Colonic Pouches. Laparoscopy / methods. Proctocolectomy, Restorative / methods. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18679748.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Interactive Tutorial
  • [Publication-country] United States
  •  go-up   go-down


45. Shibaki T, Morimoto N: [Advanced rectal cancer in an older patient, in whom metastatic liver lesions were effectively controlled with oral UFT+LV and venous CPT-11 administration--case report]. Gan To Kagaku Ryoho; 2006 Jun;33(6):825-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He was diagnosed with sigmoid colon cancer with multiple metastatic lesions in the right lobe of the liver.
  • The final diagnosis was stage IV sigmoid colon cancer with metastasis to the omentum.
  • One month after the operation, adjuvant chemotherapy with oral administration of tegafur/uracil compound (UFT) and Leucovorin (LV), and drip venous infusion of irinotecan hydrochloride (CPT-11) was initiated (UFT 300 mg/day for 14 days, LV 75 mg/day for 14 days, CPT-11 90 mg/m(2) on the 1 st day, with 1 course consisting of 21 days).
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / secondary. Rectal Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Aged, 80 and over. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Colon, Sigmoid / surgery. Colostomy. Drug Administration Schedule. Drug Combinations. Humans. Infusions, Intra-Arterial. Leucovorin / administration & dosage. Male. Omentum / pathology. Peritoneal Neoplasms / secondary. Remission Induction. Tegafur / administration & dosage. Uracil / administration & dosage

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Rectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16770106.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / UFT(R) drug; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


46. Hashimoto Y, Skacel M, Lavery IC, Mukherjee AL, Casey G, Adams JC: Prognostic significance of fascin expression in advanced colorectal cancer: an immunohistochemical study of colorectal adenomas and adenocarcinomas. BMC Cancer; 2006;6:241
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we report on the prevalence and potential clinical significance of fascin expression in relation to the progression of colorectal adenocarcinoma and to tumor cell proliferation as measured by Ki67 index.
  • In the clinically-annotated tumors, fascin immunoreactivity was more common in tumors located in the proximal colon (p = 0.009), but was not associated with age, gender, or TNM stage.
  • Patients with stage III/IV adenocarcinomas (n = 62) with strong fascin immunoreactivity had a worse prognosis than patients with low or absent fascin, (3-year overall survival of 11% versus 43% for fascin-negative patients; p = 0.023).
  • Strong and diffuse expression was seen in a subset of advanced colorectal adenocarcinomas that correlated with shorter survival in stage III and IV patients.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. Carrier Proteins / biosynthesis. Colorectal Neoplasms / genetics. Gene Expression Regulation, Neoplastic / physiology. Microfilament Proteins / biosynthesis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 May 20;355(9217):1745-50 [10832824.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8585-94 [15574765.001]
  • [Cites] Br J Cancer. 2000 Oct;83(7):870-3 [10970687.001]
  • [Cites] Am J Pathol. 2000 Dec;157(6):1947-53 [11106567.001]
  • [Cites] Curr Opin Oncol. 2001 Jan;13(1):63-9 [11148689.001]
  • [Cites] Clin Exp Metastasis. 2000;18(1):83-8 [11206843.001]
  • [Cites] J Cell Biol. 2001 Mar 19;152(6):1169-82 [11257118.001]
  • [Cites] Nature. 2001 May 17;411(6835):375-9 [11357145.001]
  • [Cites] Am J Pathol. 2001 Nov;159(5):1613-7 [11696421.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1043-8 [11844828.001]
  • [Cites] Int J Biochem Cell Biol. 2002 Jun;34(6):685-98 [11943599.001]
  • [Cites] Bioessays. 2002 Apr;24(4):350-61 [11948621.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):233-6 [12086859.001]
  • [Cites] Am J Clin Pathol. 2002 Jul;118(1):52-9 [12109856.001]
  • [Cites] Int J Cancer. 2002 Oct 10;101(5):403-8 [12216066.001]
  • [Cites] Am J Pathol. 2003 Jan;162(1):69-80 [12507891.001]
  • [Cites] Br J Cancer. 2003 Feb 24;88(4):537-47 [12592367.001]
  • [Cites] Nat Rev Cancer. 2003 May;3(5):362-74 [12724734.001]
  • [Cites] Oncogene. 2003 Jun 5;22(23):3616-23 [12789270.001]
  • [Cites] Mod Pathol. 2003 Sep;16(9):902-12 [13679454.001]
  • [Cites] N Engl J Med. 2003 Jul 17;349(3):247-57 [12867608.001]
  • [Cites] Curr Opin Cell Biol. 2004 Feb;16(1):14-23 [15037300.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1564-71 [15051756.001]
  • [Cites] Curr Opin Cell Biol. 2004 Oct;16(5):590-6 [15363811.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Oct;5(10):816-26 [15459662.001]
  • [Cites] Gene Expr Patterns. 2004 Oct;4(6):637-43 [15465486.001]
  • [Cites] Cell. 1996 Feb 9;84(3):345-57 [8608588.001]
  • [Cites] Science. 1996 May 24;272(5265):1187-90 [8638166.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13927-31 [9391129.001]
  • [Cites] Mol Biol Cell. 1998 May;9(5):993-1006 [9571235.001]
  • [Cites] Semin Cancer Biol. 1999 Aug;9(4):245-54 [10448112.001]
  • [Cites] Oncology. 2004;67(3-4):262-70 [15557788.001]
  • [Cites] J Surg Oncol. 2004 Dec 15;88(4):261-6 [15565587.001]
  • [Cites] Hum Genomics. 2004 Jan;1(2):134-40 [15601541.001]
  • [Cites] Curr Opin Genet Dev. 2005 Feb;15(1):87-96 [15661538.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):186-92 [15671545.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2597-605 [15814639.001]
  • [Cites] Int J Biochem Cell Biol. 2005 Sep;37(9):1787-804 [16002322.001]
  • [Cites] Nature. 2005 Jul 28;436(7050):518-24 [16049480.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Nov 11;337(1):355-62 [16185662.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1533-9 [16533778.001]
  • [ErratumIn] BMC Cancer. 2011;11:488
  • (PMID = 17029629.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Microfilament Proteins; 146808-54-0 / fascin
  • [Other-IDs] NLM/ PMC1615879
  •  go-up   go-down


47. Heidrich DE: Delirium: an under-recognized problem. Clin J Oncol Nurs; 2007 Dec;11(6):805-7
Hazardous Substances Data Bank. MORPHINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE STUDY: Ms. G, a 78-year-old woman with a history of heart failure and a left ventricular ejection fraction of 45%, had an exploratory laparotomy with colon resection and colostomy two days ago for an obstructive stage IIIB adenocarcinoma of the colon.
  • She has a patient-controlled analgesia (PCA) pump for postoperative pain control with 1 mg of morphine available every 30 minutes; she used a total of 4 mg of morphine via IV since midnight. Ms. G requires belladonna and opium suppositories about every eight hours to treat bladder spasms associated with her urinary catheter.
  • [MeSH-minor] Adenocarcinoma / surgery. Aged. Belladonna Alkaloids / adverse effects. Causality. Colonic Neoplasms / surgery. Colostomy / adverse effects. Early Diagnosis. Female. Humans. Morphine / adverse effects. Nursing Assessment. Opium / adverse effects. Pain, Postoperative / drug therapy. Pain, Postoperative / etiology. Postoperative Care / methods. Postoperative Care / nursing. Urinary Catheterization / adverse effects

  • MedlinePlus Health Information. consumer health - Delirium.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18063538.001).
  • [ISSN] 1092-1095
  • [Journal-full-title] Clinical journal of oncology nursing
  • [ISO-abbreviation] Clin J Oncol Nurs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 0 / Belladonna Alkaloids; 76I7G6D29C / Morphine; 8008-60-4 / Opium
  •  go-up   go-down


48. Niinobu T, Nakagawa S, Itani Y, Nishikawa Y, Amano M, Higaki N, Hayashida H, Sakon M: [Rectal stenosis due to Schnitzler metastasis following surgery for gastric cancer--a case successfully treated with TS-1 and CDDP combination chemotherapy]. Gan To Kagaku Ryoho; 2005 Oct;32(11):1761-4
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The lesion was judged to be P1, SE, H0, N2 and Stage IV and the patient was managed on a regular schedule as an outpatient.
  • A fiber optic examination of the sigmoid colon detected an ulcerous lesion with a hemorrhage at the anterior rectal wall.
  • A biopsy revealed the lesion to be Group V poorly differentiated adenocarcinoma.
  • After 3 courses of this regimen, a fiber optic examination of the colon conducted in February 2005 no longer detected the rectal tumor, leaving only a cicatrix.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Rectal Diseases / drug therapy. Rectal Neoplasms / drug therapy. Rectal Neoplasms / secondary. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Rectal Disorders.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16315933.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


49. Jung SH, Kim HC, Yu CS, Chang HM, Ryu MH, Lee JL, Kim JS, Kim JC: [Clinicopathologic characteristics of colorectal neuroendocrine tumor]. Korean J Gastroenterol; 2006 Aug;48(2):97-103
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nine tumors were located in the rectum, two in the sigmoid, and each one in the transverse colon and cecum, respectively.
  • All patients were advanced at the time of diagnosis, with AJCC TNM staging: stage IIIB (n=2), stage IIIC (n=3), and stage IV (n=8).
  • Five patients who received chemotherapy showed median survival of 32 months (stage III) and 17.5 months (stage IV), whereas other five patients without chemotherapy died with a median survival of 6.2 months.
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Biomarkers, Tumor / immunology. Biopsy. Chromogranin A / analysis. Chromogranin A / immunology. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Retrospective Studies. Sigmoid Neoplasms / drug therapy. Sigmoid Neoplasms / mortality. Sigmoid Neoplasms / pathology. Synaptophysin / analysis. Synaptophysin / immunology

  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16929153.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromogranin A; 0 / Synaptophysin
  •  go-up   go-down


50. Widder J, Herbst F, Dobrowsky W, Schmid R, Pokrajac B, Jech B, Chiari C, Stift A, Maier A, Karner-Hanusch J, Teleky B, Wrba F, Jakesz R, Poetter R: Preoperative short-term radiation therapy (25 Gy, 2.5 Gy twice daily) for primary resectable rectal cancer (phase II). Br J Cancer; 2005 Apr 11;92(7):1209-14
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 1) with clinical T3Nx rectal adenocarcinoma received preoperative pelvic radiation therapy with single fractions of 2.5 Gy twice daily (interval 6 h between fractions) to a total dose of 25 Gy within 1 week.
  • Postoperative histology revealed UICC stage I in 33%, stage II in 26%, stage III in 34%, and stage IV in 7% of the patients.
  • Disease-specific and disease-free survivals at 4 years (excluding stage IV) were 82 and 69%, respectively.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Neoplasm Recurrence, Local. Rectal Neoplasms / radiotherapy. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1997 Apr 3;336(14):980-7 [9091798.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):281-7 [9069298.001]
  • [Cites] Dis Colon Rectum. 1998 May;41(5):543-9; discussion 549-51 [9593234.001]
  • [Cites] Acta Oncol. 1999;38(7):883-93 [10606418.001]
  • [Cites] J Natl Cancer Inst. 2000 Mar 1;92(5):388-96 [10699069.001]
  • [Cites] JAMA. 2000 Aug 23-30;284(8):1008-15 [10944647.001]
  • [Cites] Radiother Oncol. 2000 Sep;56(3):341-7 [10974384.001]
  • [Cites] Lancet. 2001 Feb 17;357(9255):497-504 [11229667.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] Lancet. 2001 Oct 20;358(9290):1291-304 [11684209.001]
  • [Cites] Eur J Cancer. 2002 Jul;38(11):1429-36 [12110487.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4361-7 [12409336.001]
  • [Cites] Br Med Bull. 2002;64:141-57 [12421731.001]
  • [Cites] JAMA. 1990 Sep 19;264(11):1444-50 [2202842.001]
  • [Cites] Lancet. 1993 Feb 20;341(8843):457-60 [8094488.001]
  • [Cites] Radiother Oncol. 1997 Aug;44(2):123-36 [9288840.001]
  • (PMID = 15785745.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2361979
  •  go-up   go-down


51. Mikhaĭlova EI, Pimanov SI, Voropaev EV: [Fecal oncomarkers in the diagnostics of colorectal cancer]. Klin Med (Mosk); 2007;85(12):62-7
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In approximately every third patient, colon cancer is revealed at stage IV, which determines the patient's outcome.
  • Early diagnosis is possible only at the pre-clinical stage.
  • Immunochemical occult blood test proved to be more sensitive for the detection of polyps or any kind of colon dysplasia (p < 0.05).
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / metabolism. Colorectal Neoplasms / diagnosis. Feces / chemistry. Leukocyte L1 Antigen Complex / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Bowel Movement.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18318171.001).
  • [ISSN] 0023-2149
  • [Journal-full-title] Klinicheskaia meditsina
  • [ISO-abbreviation] Klin Med (Mosk)
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Leukocyte L1 Antigen Complex
  •  go-up   go-down


52. Kornmann M, Staib L, Wiegel T, Kreuser ED, Kron M, Baumann W, Henne-Bruns D, Link KH: Adjuvant chemoradiotherapy of advanced resectable rectal cancer: results of a randomised trial comparing modulation of 5-fluorouracil with folinic acid or with interferon-α. Br J Cancer; 2010 Oct 12;103(8):1163-72
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Patients with R(0)-resected rectal cancer (UICC stage II and III) were stratified and randomised to a 12-month adjuvant chemoradiotherapy with 5-FU, 5-FU+FA, or 5-FU+IFNα.
  • Toxicities (WHO III+IV) were observed in 32, 28, and 58% of patients receiving 5-FU, 5-FU+FA, and 5-FU+IFNα, respectively.
  • A subgroup analysis in stage II (pT3/4pN0) disease (n=271) revealed that the addition of FA tended to reduce the 5-year local recurrence (LR) rate by 55% and increase recurrence-free survival and OS rates by 12 and 13%, respectively, relative to 5-FU alone.
  • In UICC stage II disease, the addition of FA tended to lower LR and increased survival.
  • The addition of FA to 5-FU may be an effective option for adjuvant chemoradiotherapy of UICC stage II rectal cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1991 Mar 14;324(11):709-15 [1997835.001]
  • [Cites] J Clin Oncol. 1995 Apr;13(4):921-8 [7707120.001]
  • [Cites] Lancet. 1995 Apr 15;345(8955):939-44 [7715291.001]
  • [Cites] N Engl J Med. 1997 Apr 3;336(14):980-7 [9091798.001]
  • [Cites] Dis Colon Rectum. 1997 Feb;40(2):131-9 [9075745.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):295-300 [9440756.001]
  • [Cites] J Clin Oncol. 2005 Jul 10;23(20):4545-52 [16002846.001]
  • [Cites] Ann Surg. 2005 Aug;242(2):178-87 [16041207.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8671-8 [16314627.001]
  • [Cites] Acta Oncol. 2005;44(8):904-12 [16332600.001]
  • [Cites] N Engl J Med. 2006 Sep 14;355(11):1114-23 [16971718.001]
  • [Cites] Br J Surg. 2006 Oct;93(10):1215-23 [16983741.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4620-5 [17008704.001]
  • [Cites] Strahlenther Onkol. 2007 May;183(5):227-35 [17497093.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2198-204 [17470851.001]
  • [Cites] J Clin Oncol. 2007 Oct 1;25(28):4379-86 [17906203.001]
  • [Cites] Ann Surg. 2007 Nov;246(5):693-701 [17968156.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):303-12 [18182672.001]
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4866-8 [18711174.001]
  • [Cites] Lancet. 2009 Mar 7;373(9666):811-20 [19269519.001]
  • [Cites] Acta Oncol. 2009;48(3):368-76 [19242829.001]
  • [Cites] Eur J Cancer. 2009 May;45(7):1175-83 [19128956.001]
  • [Cites] J Clin Oncol. 2009 Jul 1;27(19):3109-16 [19451431.001]
  • [Cites] Clin Colorectal Cancer. 2009 Oct;8(4):194-9 [19822509.001]
  • [Cites] Acta Oncol. 2010 Apr;49(3):278-86 [20180626.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Oct 1;78(2):472-8 [20133081.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10):2726-34 [10537335.001]
  • [Cites] Semin Oncol. 1999 Dec;26(6):663-71 [10606259.001]
  • [Cites] J Natl Cancer Inst. 2000 Mar 1;92(5):388-96 [10699069.001]
  • [Cites] Lancet. 2000 May 6;355(9215):1588-96 [10821362.001]
  • [Cites] Ann Oncol. 2000 Apr;11(4):385-91 [10847455.001]
  • [Cites] Lancet. 2000 Jul 8;356(9224):93-6 [10963244.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1787-94 [11251010.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1744-50 [11919230.001]
  • [Cites] Dis Colon Rectum. 2002 Jul;45(7):857-66 [12130870.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):386-96 [12243812.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4116-24 [14519634.001]
  • [Cites] Br J Surg. 2004 Jan;91(1):121-3 [14716805.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] N Engl J Med. 1985 Jun 6;312(23):1465-72 [2859523.001]
  • [Cites] J Natl Cancer Inst. 1988 Mar 2;80(1):21-9 [3276900.001]
  • [Cites] JAMA. 1990 Sep 19;264(11):1444-50 [2202842.001]
  • (PMID = 20877353.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interferon-alpha; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2967051
  •  go-up   go-down


53. de Ferro SM, Suspiro A, Fidalgo P, Lage P, Rodrigues P, Fragoso S, Vitoriano I, Baltazar C, Albuquerque C, Bettencourt A, Leitão CN: Aggressive phenotype of MYH-associated polyposis with jejunal cancer and intra-abdominal desmoid tumor: report of a case. Dis Colon Rectum; 2009 Apr;52(4):742-5
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At aged 35 years, Spigelman Stage IV duodenal adenomatosis was detected.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenoma / genetics. Adult. DNA Glycosylases / genetics. Duodenal Neoplasms / genetics. Genetic Predisposition to Disease. Germ-Line Mutation. Humans. Intestinal Neoplasms / genetics. Intestinal Obstruction / etiology. Liver Neoplasms / secondary. Male. Mesentery. Mutation. Phenotype. Syndrome

  • Genetic Alliance. consumer health - Desmoid Tumor.
  • Genetic Alliance. consumer health - MYH-associated polyposis.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404084.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.2.2.- / DNA Glycosylases
  •  go-up   go-down


54. Roque VM, Forones NM: [Evaluation of the toxicity and quality of life in patients with colorectal cancer treated with chemotherapy]. Arq Gastroenterol; 2006 Apr-Jun;43(2):94-101
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Avaliação da qualidade de vida e toxicidades em pacientes com câncer colorretal tratados com quimioterapia adjuvante baseada em fluoropirimidinas.
  • According to the International Union Against Cancer classification, 34 patients (75.6%) had tumors stage II or III and 11 had tumors stage IV (24.4%), 64.4% were in the colon.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Colorectal Neoplasms / drug therapy. Quality of Life

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17119662.001).
  • [ISSN] 0004-2803
  • [Journal-full-title] Arquivos de gastroenterologia
  • [ISO-abbreviation] Arq Gastroenterol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 12001-76-2 / Vitamin B Complex; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


55. Shiba Y, Umekita N, Noda K, Kitamura M: [A case report of recurrence of liver metastases from colorectal cancer, which seemed to have vanished for a time by intra-aortic chemotherapy]. Gan To Kagaku Ryoho; 2005 Oct;32(11):1829-31
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnosis was Stage IV well-differentiated tubular adeno carcinoma. n1H3M(-).
  • As the strategy for liver metastasis of colon cancer, it is better to perform a surgical resection as soon as the focus becomes resectable.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antimetabolites, Antineoplastic / administration & dosage. Colorectal Neoplasms / pathology. Fluorouracil / administration & dosage. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16315954.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 7673326042 / irinotecan; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


56. Uña E: Atypical presentation of acute neurotoxicity secondary to oxaliplatin. J Oncol Pharm Pract; 2010 Dec;16(4):280-2
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 62-year-old female diagnosed with stage IV colon cancer, underwent palliative treatment with combination of oxaliplatin (130 mg/m( 2) on day 1), capecitabine (1.250 mg/m(2) bid on days 1 to 14 every 3 weeks), and bevacizumab.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Angiogenesis Inhibitors / administration & dosage. Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bevacizumab. Capecitabine. Colonic Neoplasms / drug therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Female. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Fluorouracil / therapeutic use. Humans. Leg. Middle Aged. Muscle Cramp / chemically induced. Muscle Cramp / drug therapy. Palliative Care. Paresthesia / chemically induced. Paresthesia / drug therapy. Treatment Outcome

  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20015928.001).
  • [ISSN] 1477-092X
  • [Journal-full-title] Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  • [ISO-abbreviation] J Oncol Pharm Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 2S9ZZM9Q9V / Bevacizumab; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


57. Seleye-Fubara D, Gbobo I: Pathological study of colorectal carcinoma in adult Nigerians: a study of 45 cases. Niger J Med; 2005 Apr-Jun;14(2):167-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The commonest site of this cancer is the rectum and the least occurred in the transverse colon.
  • Most of our patients presented with advanced cancer of stage IV & III of TNM classification (D and C of Astler-Coller System).
  • Patients present when the tumour is in an advanced stage hence poorer prognosis and the ages of the patents is about 10 years earlier than that of Caucasians.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16083240.001).
  • [ISSN] 1115-2613
  • [Journal-full-title] Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria
  • [ISO-abbreviation] Niger J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


58. Sadahiro S, Mitomi T, Noto T, Kumada K, Hiki Y, Yamakawa T, Amano T, Oki S, Otani Y, Oka H, Takahashi T, Takemiya S, Nishiyama K, Yamamura T, Tsuchiya S, Ogawa N, Study Group on Postoperative Adjuvant Chemotherapy in Kanagawa Prefecture: [Multicenter comparative study of the recurrence-inhibitory effect of oral fluoropyrimidine drugs in patients with colorectal cancer following curative resection]. Gan To Kagaku Ryoho; 2005 Jul;32(7):997-1005
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 501 patients consisting of 252 patients with stage III/IV colon cancer (Colorectal Cancer Handling Rules, 4th Ed.) for which macroscopic curative resection was possible and 249 patients with stage II/III/IV rectal cancer (ibid, 4th Ed.) were registered from 40 participating institutions.
  • The patients were randomly allocated to two groups with colon cancer and rectal cancer employed as stratification factors.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Fluorouracil / analogs & derivatives. Rectal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Oral cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16044962.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / UFT(R) drug; 1548R74NSZ / Tegafur; 50SG953SK6 / Mitomycin; 56HH86ZVCT / Uracil; HA82M3RAB2 / 1-hexylcarbamoyl-5-fluorouracil; U3P01618RT / Fluorouracil
  •  go-up   go-down


59. Yantiss RK, Goodarzi M, Zhou XK, Rennert H, Pirog EC, Banner BF, Chen YT: Clinical, pathologic, and molecular features of early-onset colorectal carcinoma. Am J Surg Pathol; 2009 Apr;33(4):572-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ninety-two percent of tumors from young patients occurred in the distal colon (P=0.006), particularly the rectum (58%, P=0.02), and 75% were stage III or IV.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Colorectal Neoplasms / genetics. Colorectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19047896.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / MicroRNAs; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


60. Zwahlen D, Jezioranski J, Chan P, Haider MA, Cho YB, Yeung I, Levin W, Manchul L, Fyles A, Milosevic M: Magnetic resonance imaging-guided intracavitary brachytherapy for cancer of the cervix. Int J Radiat Oncol Biol Phys; 2009 Jul 15;74(4):1157-64
International Agency for Research on Cancer - Screening Group. diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND MATERIALS: A total of 20 patients with International Federation of Gynecology and Obstetrics Stage IB-IV cervical cancer had an MRI-compatible intrauterine BT applicator inserted after external beam radiotherapy.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / radiotherapy. Adult. Aged. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Colon, Sigmoid / anatomy & histology. Feasibility Studies. Female. Humans. Middle Aged. Radiation Injuries / prevention & control. Radiotherapy Dosage. Rectum / anatomy & histology. Tumor Burden. Urinary Bladder / anatomy & histology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19101097.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


61. Coogan PF, Smith J, Rosenberg L: Statin use and risk of colorectal cancer. J Natl Cancer Inst; 2007 Jan 3;99(1):32-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Statins have anticancer activity in various cell types, including colon cancer cells.
  • METHODS: Case patients with adenocarcinoma of the colon or rectum were ascertained from participating hospitals in Massachusetts and the Massachusetts Cancer Registry from January 1, 2001, through November 30, 2004.
  • The risk of stage IV cancer was, however, statistically significantly lower among statin users than among nonusers (OR = 0.49, 95% CI = 0.26 to 0.91).
  • The reduced risk of stage IV cancer observed among statin users requires confirmation.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Statins.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17202111.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA87709
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors
  •  go-up   go-down


62. Mansilla F, Birkenkamp-Demtroder K, Kruhøffer M, Sørensen FB, Andersen CL, Laiho P, Aaltonen LA, Verspaget HW, Orntoft TF: Differential expression of DHHC9 in microsatellite stable and instable human colorectal cancer subgroups. Br J Cancer; 2007 Jun 18;96(12):1896-903
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Microarray analysis on pooled samples has previously identified ZDHHC9 (DHHC9) to be upregulated in colon adenocarcinoma compared to normal colon mucosa.
  • Immunohistochemical analysis was performed on 60 colon adenocarcinomas, previously analysed on microarrays, as well as on tissue microarrays with 40 stage I-IV tumours and 46 tumours from different organ sites.
  • In conclusion, DHHC9 is a gastrointestinal-related protein highly expressed in MSS colon tumours.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Med Chem. 1997 Sep 12;40(19):2971-90 [9301658.001]
  • [Cites] Nature. 1997 Apr 10;386(6625):623-7 [9121588.001]
  • [Cites] Cell. 1999 Jul 9;98(1):69-80 [10412982.001]
  • [Cites] Neuron. 2004 Dec 16;44(6):987-96 [15603741.001]
  • [Cites] Gut. 2005 Mar;54(3):374-84 [15710986.001]
  • [Cites] Science. 2005 Mar 18;307(5716):1746-52 [15705808.001]
  • [Cites] Br J Cancer. 2005 Jun 20;92(12):2240-8 [15956967.001]
  • [Cites] J Biol Chem. 2005 Sep 2;280(35):31141-8 [16000296.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8332-40 [16322293.001]
  • [Cites] Int J Cancer. 2006 Mar 1;118(5):1309-15 [16152604.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):1974-81 [16488996.001]
  • [Cites] Carcinogenesis. 2006 Mar;27(3):419-28 [16272173.001]
  • [Cites] J Mol Diagn. 2006 May;8(2):193-201 [16645205.001]
  • [Cites] World J Gastroenterol. 2006 Aug 7;12(29):4636-9 [16937431.001]
  • [Cites] Carcinogenesis. 2007 Jan;28(1):38-48 [16774939.001]
  • [Cites] Mol Cell Biol. 2000 Apr;20(7):2475-87 [10713171.001]
  • [Cites] Oncol Rep. 2001 Nov-Dec;8(6):1409-13 [11605075.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4352-63 [12154040.001]
  • [Cites] Sci STKE. 2002 Oct 1;2002(152):pe41 [12359913.001]
  • [Cites] Cell. 2002 Oct 18;111(2):241-50 [12408868.001]
  • [Cites] Gastroenterology. 2002 Dec;123(6):1804-11 [12454837.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):90-6 [12469123.001]
  • [Cites] Bioinformatics. 2003 Jan 22;19(2):185-93 [12538238.001]
  • [Cites] Nucleic Acids Res. 2003 Feb 15;31(4):e15 [12582260.001]
  • [Cites] N Engl J Med. 2003 Jul 17;349(3):247-57 [12867608.001]
  • [Cites] J Biol Chem. 2003 Dec 19;278(51):51957-67 [14522980.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5245-50 [15289330.001]
  • [Cites] Fam Cancer. 2004;3(2):85-91 [15340258.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] J Biol Chem. 1996 May 10;271(19):11541-7 [8626715.001]
  • [Cites] Biochem Pharmacol. 1998 Dec 1;56(11):1411-26 [9827573.001]
  • (PMID = 17519897.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / RNA, Neoplasm; EC 2.3.- / Acyltransferases; EC 2.3.1.- / ZDHHC9 protein, human
  • [Other-IDs] NLM/ PMC2359975
  •  go-up   go-down


63. Ferrigno R, Novaes PE, Silva ML, Nishimoto IN, Nakagawa WT, Rossi BM, Ferreira Fde O, Lopes A: Neoadjuvant radiochemotherapy in the treatment of fixed and semi-fixed rectal tumors. Analysis of results and prognostic factors. Radiat Oncol; 2006;1:5
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND MATERIALS: From January 1994 to December 2003, 101 patients with fixed (25%) or semi-fixed (75%) rectal adenocarcinoma were treated by preoperative radiotherapy with a dose of 45 Gy at the whole pelvis and 50.4 Gy at primary tumor, concomitant to four weekly chemotherapies with 5-Fluorouracil (425 mg/m2) and Leucovorin (20 mg/m2).
  • Age, gender, tumor fixation, tumor distance from the anal verge, clinical response, surgical technique, and postoperative TNM stage were the prognostic factors analyzed for overall survival (OS), disease-free survival (DFS), and local control (LC) at five years.
  • The postoperative TNM stage was a significant factor for DFS (I:64.1%, II:69.6%, III:35.2%, IV:11.1%; p < 0.001) and for LC (I:75.7%, II: 92.9%, III:54.1%, IV:100%; p = 0.005).

  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Radiother. 2004 Oct;8(5):297-304 [15561595.001]
  • [Cites] Dis Colon Rectum. 2004 Nov;47(11):1798-807 [15622571.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):665-77 [15708244.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1129-35 [15752893.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1847-58 [15774778.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1371-7 [15817339.001]
  • [Cites] Ann Surg. 2005 May;241(5):829-36; discussion 836-8 [15849519.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2396 [10561302.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):883-8 [10705009.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):713-8 [10837955.001]
  • [Cites] JAMA. 2000 Aug 23-30;284(8):1008-15 [10944647.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):843-56 [11020583.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):1075-80 [11072165.001]
  • [Cites] Ann Surg Oncol. 2000 Dec;7(10):727-31 [11129419.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1779-86 [11251009.001]
  • [Cites] Ann Surg Oncol. 2001 Mar;8(2):163-9 [11258782.001]
  • [Cites] Am J Clin Oncol. 2001 Apr;24(2):107-12 [11319280.001]
  • [Cites] Ann Surg Oncol. 2001 May;8(4):311-8 [11352304.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):659-63 [11395233.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):176-83 [11516868.001]
  • [Cites] Cancer. 2001 Aug 15;92(4):896-902 [11550163.001]
  • [Cites] Ann Surg Oncol. 2001 Dec;8(10):801-6 [11776494.001]
  • [Cites] J Am Coll Surg. 2002 Feb;194(2):131-5; discussion 135-6 [11848629.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):294-303 [11872273.001]
  • [Cites] Ann Surg. 2002 Apr;235(4):493-8 [11923604.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):664-74 [12062610.001]
  • [Cites] Ann Surg Oncol. 2002 Jul;9(6):568-73 [12095973.001]
  • [Cites] Ann Surg. 2002 Jul;236(1):75-81 [12131088.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1460-5 [12459370.001]
  • [Cites] Cancer. 2003 Jan 15;97(2):517-24 [12518377.001]
  • [Cites] Dis Colon Rectum. 2003 Feb;46(2):192-202 [12576893.001]
  • [Cites] Dis Colon Rectum. 2003 Mar;46(3):298-304 [12626903.001]
  • [Cites] Dis Colon Rectum. 2003 Apr;46(4):448-53 [12682535.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):84-9 [12909219.001]
  • [Cites] Dis Colon Rectum. 2003 Sep;46(9):1189-93 [12972962.001]
  • [Cites] Dis Colon Rectum. 2003 Sep;46(9):1194-9 [12972963.001]
  • [Cites] Semin Surg Oncol. 2003;21(4):261-4 [14648784.001]
  • [Cites] Semin Surg Oncol. 2003;21(4):265-70 [14648785.001]
  • [Cites] Eur J Cancer. 2004 Jan;40(2):219-24 [14728936.001]
  • [Cites] Tumori. 2004 May-Jun;90(3):303-9 [15315310.001]
  • [Cites] Dis Colon Rectum. 2004 Aug;47(8):1323-30 [15484346.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] J Clin Oncol. 1992 Aug;10(8):1218-24 [1634912.001]
  • [Cites] Cancer. 1993 Jun 1;71(11):3486-92 [8490898.001]
  • [Cites] Oncology (Williston Park). 1989 May;3(5):137-42; discussion 142, 146-8 [2577881.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):169-75 [8083110.001]
  • [Cites] Radiother Oncol. 1994 Aug;32(2):116-23 [7972904.001]
  • [Cites] Cancer Invest. 1995;13(1):96-107 [7834479.001]
  • [Cites] Cancer. 1995 May 1;75(9):2269-75 [7712435.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1409-16 [7751886.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 30;32(5):1473-5 [7635791.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):281-7 [9069298.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):289-95 [9069299.001]
  • [Cites] N Engl J Med. 1997 Apr 3;336(14):980-7 [9091798.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):893-900 [15936575.001]
  • [Cites] Semin Oncol. 1995 Dec;22(6):611-24 [8539636.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jul 15;35(5):1039-48 [8751414.001]
  • [Cites] Cancer. 1996 Sep 1;78(5):968-76 [8780533.001]
  • [Cites] Ann Surg Oncol. 1996 Sep;3(5):419-20 [8876881.001]
  • [Cites] Oncology (Williston Park). 1996 Nov;10(11):1701-8, 1713-4; discussion 1714-18 [8953589.001]
  • [Cites] Lancet. 1996 Dec 14;348(9042):1605-10 [8961989.001]
  • [Cites] Dis Colon Rectum. 1997 Feb;40(2):131-9 [9075745.001]
  • [Cites] Radiographics. 1997 May-Jun;17(3):609-26 [9153700.001]
  • [Cites] Radiology. 1997 Aug;204(2):533-8 [9240549.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Feb 1;40(3):569-74 [9486606.001]
  • [Cites] Ann Surg Oncol. 1998 Mar;5(2):113-8 [9527263.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Mar 15;40(5):1067-75 [9539561.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):51-7 [9747819.001]
  • [Cites] Ann Surg. 1999 Apr;229(4):493-7 [10203081.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jul 15;44(5):1027-38 [10421535.001]
  • (PMID = 16722598.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC1459184
  • [General-notes] NLM/ Original DateCompleted: 20060619
  •  go-up   go-down


64. Fujita Y, Terashima M, Hoshino Y, Ohtani S, Kashimura S, Kanzaki N, Osuka F, Kogure M, Gotoh M: Detection of cancer cells disseminated in bone marrow using real-time quantitative RT-PCR of CEA, CK19, and CK20 mRNA in patients with gastric cancer. Gastric Cancer; 2006;9(4):308-14
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The detection limits of these genes were determined in the gastric cancer cell line MKN-45 and the colon cancer cell line C-1, which had been serially diluted in peripheral blood mononuclear cells (PBMCs).
  • In the clinical samples, only 1 of the 65 gastric cancer patients (1.5%) who had stage IV disease was positive for CEA, CK19, and CK20 mRNA; none of CEA, CK19, or CK20 mRNA was positive in the remaining 64 patients.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / genetics. Adenocarcinoma, Papillary / metabolism. Adenocarcinoma, Papillary / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Bone Marrow / metabolism. Bone Marrow / pathology. Carcinoma, Signet Ring Cell / genetics. Carcinoma, Signet Ring Cell / metabolism. Carcinoma, Signet Ring Cell / pathology. Female. Humans. Keratin-20 / genetics. Keratin-20 / metabolism. Liver Neoplasms / genetics. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Lymphatic Metastasis / pathology. Male. Middle Aged. Peritoneal Neoplasms / genetics. Peritoneal Neoplasms / metabolism. Peritoneal Neoplasms / secondary. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gastric Cancer. 2006;9(4):243-4 [17235624.001]
  • (PMID = 17235634.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / KRT20 protein, human; 0 / Keratin-19; 0 / Keratin-20; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  •  go-up   go-down


65. Woznick AR, Braddock AL, Dulai M, Seymour ML, Callahan RE, Welsh RJ, Chmielewski GW, Zelenock GB, Shanley CJ: Lysyl oxidase expression in bronchogenic carcinoma. Am J Surg; 2005 Mar;189(3):297-301
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent studies have documented differential lysyl oxidase expression in the stromal reaction to colon, breast, prostate, and lung cancer.
  • The present study was undertaken to test the hypothesis that lysyl oxidase mRNA and protein expression decrease with advancing tumor stage in patients with bronchogenic carcinoma.
  • RESULTS: Real-time polymerase chain reaction studies documented a 3.4-fold graded decrease in lysyl oxidase mRNA levels as tumors progressed from stage I to IV.
  • [MeSH-major] Adenocarcinoma / enzymology. Carcinoma, Bronchogenic / enzymology. Lung Neoplasms / enzymology. Protein-Lysine 6-Oxidase / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15792754.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 1.4.3.13 / Protein-Lysine 6-Oxidase
  •  go-up   go-down


66. Ragazzi E, Pucciarelli S, Seraglia R, Molin L, Agostini M, Lise M, Traldi P, Nitti D: Multivariate analysis approach to the plasma protein profile of patients with advanced colorectal cancer. J Mass Spectrom; 2006 Dec;41(12):1546-53
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using matrix-assisted laser desorption/ionization-mass spectrometry (MALDI-MS), the plasma protein profile was determined in nine stage IV CRC patients (study group) and nine clean-colon healthy subjects (control group).
  • [MeSH-major] Adenocarcinoma / blood. Biomarkers, Tumor / analysis. Colorectal Neoplasms / blood. Proteomics / methods. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17117375.001).
  • [ISSN] 1076-5174
  • [Journal-full-title] Journal of mass spectrometry : JMS
  • [ISO-abbreviation] J Mass Spectrom
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Proteins
  •  go-up   go-down


67. Tsai WS, Changchien CR, Yeh CY, Chen JS, Tang R, Chiang JM, Hsieh PS, Fan CW, Wang JY: Preoperative plasma vascular endothelial growth factor but not nitrite is a useful complementary tumor marker in patients with colorectal cancer. Dis Colon Rectum; 2006 Jun;49(6):883-94
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Preoperative plasma vascular endothelial growth factor levels were positively correlated with tumor stage, T class, M class, and tumor size (Spearman correlation, P < 0.01), but were not associated with gender, N class, tumor location, histology type, or grade.
  • The positive rates of vascular endothelial growth factor elevation (>148.6 pg/ml) compared with carcinoembryonic antigen elevation were 36.9 to 14.6 percent in Stage I, 60.9 to 33 percent in Stage II, 62.9 to 48.7 percent in Stage III, and 86 to 70.2 percent in Stage IV, respectively.
  • [MeSH-major] Adenocarcinoma / blood. Adenocarcinoma / pathology. Colorectal Neoplasms / blood. Colorectal Neoplasms / pathology. Nitrites / blood. Vascular Endothelial Growth Factor A / blood

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16741643.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nitrites; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


68. Fukuda Y, Fujio N, Ihara T, Takatori H, Tsukazaki T, Koyama I, Tsukazaki Y, Osugi H: [A case of cecal cancer with multiple liver metastases responding to irinotecan (CPT-11)/cisplatin (CDDP) combination therapy for elevation of CA19-9 after complete response (CR) by l-leucovorin(LV)/5-fluorouracil(5-FU) therapy]. Gan To Kagaku Ryoho; 2005 Nov;32(12):1949-52
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pathological examination demonstrated II, 5.0 x 2.5 cm, mod, se, INFgamma, ly(1), v(1), n(2), stage IV.
  • Low-dose CPT-11/CDDP therapy may be useful for patients with advanced colon cancer thought to be resistant to 5-FU as second-line chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. CA-19-9 Antigen / blood. Cecal Neoplasms / drug therapy. Liver Neoplasms / secondary

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16282733.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / CA-19-9 Antigen; 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


69. Ribatti D, Guidolin D, Marzullo A, Nico B, Annese T, Benagiano V, Crivellato E: Mast cells and angiogenesis in gastric carcinoma. Int J Exp Pathol; 2010 Aug;91(4):350-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The results showed that stage IV gastric carcinoma has a higher degree of vascularization than other stages and that both tryptase- and chymase-positive mast cells increase in parallel with malignancy grade even if the density of chymase-positive mast cells was significantly lower than the density of tryptase-positive mast cells and is highly correlated with the extent of angiogenesis.
  • [MeSH-major] Adenocarcinoma / blood supply. Adenocarcinoma / pathology. Mast Cells / pathology. Microvessels / pathology. Neovascularization, Pathologic / pathology. Stomach Neoplasms / blood supply. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1999 Oct 15;86(8):1455-62 [10526273.001]
  • [Cites] Methods Mol Biol. 2006;315:53-62 [16110148.001]
  • [Cites] Int J Cancer. 2000 Jan 15;85(2):171-5 [10629073.001]
  • [Cites] Br J Cancer. 2000 Jan;82(1):167-70 [10638985.001]
  • [Cites] Virchows Arch. 2000 Mar;436(3):243-8 [10782883.001]
  • [Cites] Ann Thorac Surg. 2000 Jun;69(6):1686-90 [10892907.001]
  • [Cites] Surgery. 2000 Sep;128(3):408-16 [10965312.001]
  • [Cites] Hum Pathol. 2000 Aug;31(8):955-60 [10987256.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2145-53 [11280779.001]
  • [Cites] J Histochem Cytochem. 2001 Aug;49(8):1061-2 [11457936.001]
  • [Cites] J Clin Pathol. 2001 Dec;54(12):940-4 [11729214.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1680-4 [12200681.001]
  • [Cites] World J Gastroenterol. 2002 Dec;8(6):994-8 [12439912.001]
  • [Cites] Histopathology. 2003 Mar;42(3):246-50 [12605644.001]
  • [Cites] Eur J Cancer. 2003 Mar;39(5):666-74 [12628847.001]
  • [Cites] Eur J Clin Invest. 2003 May;33(5):420-5 [12760367.001]
  • [Cites] Leukemia. 2003 Jul;17(7):1428-30 [12835741.001]
  • [Cites] Eur J Haematol. 2003 Aug;71(2):137-9 [12890156.001]
  • [Cites] Mol Cancer Ther. 2004 Sep;3(9):1041-8 [15367698.001]
  • [Cites] Surg Gynecol Obstet. 1966 Jul;123(1):3-9 [5947123.001]
  • [Cites] Pediatrics. 1982 Jul;70(1):48-51 [7088632.001]
  • [Cites] J Clin Invest. 1989 Nov;84(5):1657-62 [2553780.001]
  • [Cites] J Biol Chem. 1994 Apr 1;269(13):9416-9 [8144524.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):477-81 [7531224.001]
  • [Cites] J Biol Chem. 1995 Mar 3;270(9):4689-96 [7876240.001]
  • [Cites] Dis Colon Rectum. 1995 Mar;38(3):290-3 [7882795.001]
  • [Cites] Cancer. 1996 Mar 1;77(5):858-63 [8608475.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2671-6 [8653715.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):826-32 [9053510.001]
  • [Cites] Br J Cancer. 1997;75(4):566-71 [9052412.001]
  • [Cites] J Clin Invest. 1997 Jun 1;99(11):2691-700 [9169499.001]
  • [Cites] J Surg Oncol. 1997 Aug;65(4):232-6 [9274786.001]
  • [Cites] Am J Pathol. 1998 Jan;152(1):93-100 [9422527.001]
  • [Cites] Clin Cancer Res. 1998 Feb;4(2):429-34 [9516932.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Nov;2(11):562-77 [16270097.001]
  • [Cites] Am J Obstet Gynecol. 2005 Dec;193(6):1961-5 [16325597.001]
  • [Cites] Int J Mol Med. 2006 Jun;17(6):981-7 [16685405.001]
  • [Cites] Oncogene. 2006 Jul 20;25(31):4257-66 [16518413.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5201-6 [17114652.001]
  • [Cites] Leukemia. 2007 Jan;21(1):44-52 [16990761.001]
  • [Cites] Neurobiol Aging. 2008 Jun;29(6):926-36 [17258840.001]
  • [Cites] Indian J Pathol Microbiol. 2009 Jan-Mar;52(1):20-4 [19136773.001]
  • [Cites] Int Rev Cell Mol Biol. 2009;275:89-131 [19491054.001]
  • [Cites] J Cell Mol Med. 2009 Sep;13(9A):2822-33 [19538473.001]
  • [Cites] Br J Cancer. 1998 Jun;77(11):1900-6 [9667666.001]
  • [Cites] Int J Cancer. 1998 Sep 11;77(6):933-6 [9714067.001]
  • [Cites] Clin Cancer Res. 1996 Oct;2(10):1679-84 [9816116.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):451-5 [10027312.001]
  • [Cites] Clin Exp Allergy. 2004 Nov;34(11):1660-4 [15544587.001]
  • [Cites] Anticancer Res. 2005 Jan-Feb;25(1A):17-22 [15816514.001]
  • [Cites] Br J Cancer. 1999 Oct;81(4):647-53 [10574250.001]
  • (PMID = 20412338.001).
  • [ISSN] 1365-2613
  • [Journal-full-title] International journal of experimental pathology
  • [ISO-abbreviation] Int J Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD31; EC 3.4.21.39 / Chymases; EC 3.4.21.59 / Tryptases
  • [Other-IDs] NLM/ PMC2962893
  •  go-up   go-down


70. D'Annibale A, Morpurgo E, Fiscon V, Termini B, Serventi A, Sovernigo G, Orsini C: Minimally invasive resection for colorectal cancer: perioperative and medium-term results in an unselected patient group at a single institution. Tech Coloproctol; 2006 Dec;10(4):303-7
Genetic Alliance. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In the study period, 302 patients (mean age 66.1 years; range, 32-93 years) underwent 114 left hemicolectomies, 108 low anterior resections, 61 right hemicolectomies, 12 Miles procedures, 4 subtotal colectomies, and 3 transverse colon resections.
  • Cancer-related survival curves showed a 90% survival for stage II, 85% for stage III, and 10% for stage IV disease, 30 months after surgery.
  • [MeSH-major] Adenocarcinoma / surgery. Colectomy / methods. Colonic Neoplasms / surgery. Laparoscopy. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Tech Coloproctol. 2009 Mar;13(1):103
  • (PMID = 17115319.001).
  • [ISSN] 1123-6337
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


71. Qureshi AU, Iqbal M, Gondal KM: Transhiatal esophageal surgery for malignancy--a 7-year experience at a tertiary care hospital. J Coll Physicians Surg Pak; 2009 Jul;19(7):413-6
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All underwent transhiatal esophagectomy and gastric tube or colon was used as the conduit to restore continuity.
  • The TNM staging were stage I, IIa, IIb, III and IV in zero (0), 5 (11%), 10 (22%), 24 (57.8%) and 3 (7.1%) respectively.
  • The frequency of complications is lower as compared to transthoracic approach and the early stage of presentation can lead to high 5-year survival ratios.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / surgery. Esophagectomy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19576147.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


72. Sultan I, Rodriguez-Galindo C, El-Taani H, Pastore G, Casanova M, Gallino G, Ferrari A: Distinct features of colorectal cancer in children and adolescents: a population-based study of 159 cases. Cancer; 2010 Feb 1;116(3):758-65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common sites of involvement were the rectum (27%) and the transverse colon (26%).
  • Adenocarcinoma was the most common histotype in both adults and pediatric patients; however, children/adolescents had more unfavorable histotypes (ie, mucinous adenocarcinoma [22%] and signet ring cell carcinoma [18%]) when compared with adults (10% and 1%, respectively; P < .001).
  • Poorly differentiated and undifferentiated tumors (grades III and IV, respectively) and distant stage were more common in children/adolescents (P < .001).

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 American Cancer Society.
  • (PMID = 19957323.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


73. Lang K, Lines LM, Lee DW, Korn JR, Earle CC, Menzin J: Trends in healthcare utilization among older Americans with colorectal cancer: a retrospective database analysis. BMC Health Serv Res; 2009;9:227
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Cohorts included patients aged 66+ newly diagnosed with adenocarcinoma of the colon (n = 52,371) or rectum (n = 18,619) between 1992 and 2002 and matched patients from the general Medicare population, followed until death or December 31, 2005.
  • Resource use, including the percentage that used each type of resource, number of hospitalizations, and number of hospital and skilled nursing facility days, was evaluated by stage and subsite.
  • Hospice use rates in the last year of life were calculated by year of service, stage, and subsite for CRC patients who died of CRC.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Public Health. 2000 May;90(5):695-8 [10800415.001]
  • [Cites] Clin Gastroenterol Hepatol. 2009 Feb;7(2):198-204 [18849013.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-104-17 [12187175.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):728-35 [12586813.001]
  • [Cites] JAMA. 2003 May 7;289(17):2238-45 [12734135.001]
  • [Cites] Am J Med. 2003 Jul;115(1):47-53 [12867234.001]
  • [Cites] J Palliat Med. 2003 Oct;6(5):757-68 [14622455.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):315-21 [14722041.001]
  • [Cites] Med Care. 2004 Feb;42(2):116-22 [14734948.001]
  • [Cites] Health Serv Res. 2004 Aug;39(4 Pt 1):969-83 [15230937.001]
  • [Cites] J Clin Epidemiol. 1992 Jun;45(6):613-9 [1607900.001]
  • [Cites] Med Care. 1993 Aug;31(8):732-48 [8336512.001]
  • [Cites] Palliat Med. 2005 Mar;19(2):160-2 [15810757.001]
  • [Cites] J Clin Epidemiol. 2005 Apr;58(4):323-37 [15862718.001]
  • [Cites] J Pain Symptom Manage. 2007 Mar;33(3):238-46 [17349493.001]
  • [Cites] J Womens Health (Larchmt). 2007 Mar;16(2):214-27 [17388738.001]
  • [Cites] Int J Cancer. 2007 Aug 15;121(4):871-7 [17417782.001]
  • [Cites] Soc Sci Med. 2007 Oct;65(7):1466-78 [17600605.001]
  • [Cites] Health Econ. 2008 Aug;17(8):947-59 [17910108.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-3-18 [12187163.001]
  • (PMID = 20003294.001).
  • [ISSN] 1472-6963
  • [Journal-full-title] BMC health services research
  • [ISO-abbreviation] BMC Health Serv Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2797788
  •  go-up   go-down


74. Looi LM, Ng MH, Cheah PL: Telomerase activation in neoplastic cell immortalization and tumour progression. Malays J Pathol; 2007 Jun;29(1):33-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This is in contrast to normal somatic cells which are subject to a "mitotic clock," a phenomenon that has been linked to telomeric shortening after each round of cell replication, so that eventually the loss of genetic material reaches a critical stage and the cells undergo senescence and cell death.
  • Specimens comprised 33 breast lesions (10 infiltrating breast adenocarcinoma, 13 fibroadenoma and 10 non-neoplastic breast tissue), 27 colonic lesions (17 colonic adenocarcinoma and 10 non-neoplastic colonic mucosa) and 42 cervical lesions (20 cervical carcinoma and 22 non-neoplastic cervical tissues).
  • Telomerase activity was found in 6 (60%) of 10 breast carcinomas, 6 (46%) of 13 fibroadenomas, none of the 10 nonneoplastic breast samples, 3 (17.6%) of 17 colon carcinomas and none of the 10 non-neoplastic colonic mucosal samples, 12 (60%) of 20 cervical carcinoma and 3 (13.6%) of 22 non-neoplastic cervical samples.
  • 5/10 (50%) Stage I, 4/7 (57%) Stage II, 2/2 (100%) Stage III and 1/1 (100%) Stage IV cervical carcinomas showed telomerase activity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19105326.001).
  • [ISSN] 0126-8635
  • [Journal-full-title] The Malaysian journal of pathology
  • [ISO-abbreviation] Malays J Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Malaysia
  • [Chemical-registry-number] EC 2.7.7.49 / Telomerase
  •  go-up   go-down


75. Sastre J, Maestro ML, Puente J, Veganzones S, Alfonso R, Rafael S, García-Saenz JA, Vidaurreta M, Martín M, Arroyo M, Sanz-Casla MT, Díaz-Rubio E: Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. Ann Oncol; 2008 May;19(5):935-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Only stage correlated with positive CTCs (20.7% in stage II, 24.1% in stage III and 60.7% in stage IV, P = 0.005).
  • CONCLUSIONS: CTCs detection by CellSearch is a highly reproducible method that correlates with stage but not with other clinical and morphological variables in patients with colorectal cancer.
  • Colon cancer tumor cells are detectable in all stages.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18212090.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


76. Bedaiwy MA, Hussein MR, Biscotti C, Falcone T: Pelvic endometriosis is rarely associated with ovarian borderline tumours, cytologic and architectural atypia: a clinicopathologic study. Pathol Oncol Res; 2009 Mar;15(1):81-8
MedlinePlus Health Information. consumer health - Pelvic Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Stage IV endometriosis with extensive pelvic involvement was found in two patients.
  • Intraoperatively, the endometriotic lesions involved the ovaries (all cases); Cul de sac (four cases); urinary bladder (two cases); sigmoid colon, hemidiaphragms, and uterine vessels (one case each).
  • The endometriotic lesions were associated with uterine leiomyomas (two patients) and adenocarcinoma of the vagina (one patient).
  • One patient had recurred with metastatic adenocarcinoma of the vault.

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18575828.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down






Advertisement